
Medical Policy



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.

***Current Policy Effective Date: 5/1/25**
(See policy history boxes for previous effective dates)

Title: Transcranial Magnetic Stimulation as a Treatment of Depression and Other Psychiatric/Neurologic Disorders

Description/Background

TRANSCRANIAL MAGNETIC STIMULATION

Transcranial magnetic stimulation (TMS), introduced in 1985 as a new method of noninvasive stimulation of the brain, involves placement of a small coil over the scalp, passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex. TMS was initially used to investigate nerve conduction; eg, TMS over the motor cortex will produce a contralateral muscular-evoked potential. The motor threshold, which is the minimum intensity of stimulation required to induce a motor response, is empirically determined for each individual by localizing the site on the scalp for optimal stimulation of a hand muscle, then gradually increasing the intensity of stimulation. Interest in the use of TMS as a treatment for depression was augmented by the development of a device that could deliver rapid, repetitive stimulation. Imaging studies had shown a decrease in the activity of the left dorsolateral prefrontal cortex in depressed patients, and early studies suggested that high-frequency (eg, 5 to 10 Hz) TMS of the left dorsolateral prefrontal cortex had antidepressant effects. In contrast to electroconvulsive therapy (ECT), TMS does not require general anesthesia and does not generally induce a convulsion. Repetitive TMS (rTMS) is also being tested as a treatment for a variety of other psychiatric and neurologic disorders.

Conventional TMS delivers repeated electromagnetic pulses to induce prolonged modulation of neural activity, typically applied over the dorsolateral prefrontal cortex. High-frequency TMS (usually ≥ 10 Hz) induces an increase in neural activity whereas low-frequency TMS (usually ≤ 1 Hz) has the opposite effect. If both procedures are performed in the same session, the intervention is described as bilateral TMS.

A variety of TMS modalities have been developed, which differ on parameters including stimulation intensity, frequency, pattern, and site of the brain stimulation. Deep TMS employs an H-coil helmet design to encompass a broader surface area and stimulate deeper brain structures than conventional TMS. Theta burst stimulation is administered at lower intensities and shorter intervals than conventional TMS.

Regulatory Status

Devices for transcranial stimulation have received clearance by the U.S. Food & Drug Administration (FDA) for diagnostic uses (FDA Product Code: GWF). A number of devices subsequently received the FDA clearance for the treatment of major depressive disorder in adults who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Some of these devices use deep TMS or theta burst protocols. For example, the Brainsway Deep TMS system was FDA cleared for treatment resistant depression in 2013 based on substantial equivalence to the Neurostar TMS Therapy System, and the Horizon (Magstim) and MagVita (Tonica Elektronik) have FDA clearance for their theta burst protocols.

Indications were expanded to include treating pain associated with certain migraine headaches in 2013, and obsessive-compulsive disorder in 2018.

In 2008, the NeoPulse, now known as NeuroStar® TMS, was granted a de novo 510(k) classification by the FDA. The de novo 510(k) review process allows novel products with moderate or low-risk profiles and without predicates, which would ordinarily require premarket approval as a class III device to be down-classified in an expedited manner and brought to market with a special control as a class II device.

In 2014, the Cerena™ TMS device (eNeura Therapeutics) was granted a de novo 510(k) classification by the FDA for the acute treatment of pain associated with a migraine headache with aura. Warnings, precautions, and contraindications include the following:

- The device is only intended for patients experiencing the onset of pain associated with a migraine headache with aura.
- The device should not be used:
 - on headaches due to underlying pathology or trauma.
 - for medication overuse headaches.
- The device has not been demonstrated as safe and/or effective:
 - when treating cluster headache or a chronic migraine headache.
 - when treating during the aura phase.
 - in relieving the associated symptoms of a migraine (photophobia, phonophobia, and nausea).
 - in pregnant women, children under the age of 18, and adults over the age of 65.

In 2014, eNeura Therapeutics received 510(k) marketing clearance for the SpringTMS® for the treatment of migraine headaches. The device differs from the predicate Cerena™ TMS device with the addition of an LCD screen, a use authorization feature, a lithium battery pack, and a smaller size. The stimulation parameters are unchanged. The sTMS Mini (eNeura Therapeutics) received marketing clearance by the FDA in 2016. FDA product code: OKP.

In May 2023, eNeura, Inc received 510(k) marketing clearance for the SAVI Dual (TM) Migraine Therapy for the treatment of migraine headaches. The SAVI Dual™ Migraine Therapy device is indicated for the acute and prophylactic treatment of migraine headache in adolescents (age 12 and older) and adults.

In August 2018, the Deep TMS System (Brainsway) was granted a de novo 510(k) classification by the FDA as an adjunct for the treatment of adult patients with obsessive-compulsive disorder. The new classification applies to this device and substantially equivalent devices of this generic type.

In March 2024, NeuroStar Advanced Therapy System (Neuronetics, Inc) received 510(k) clearance by the FDA as an adjunct for the treatment of adolescent patients (age 15-21) with Major Depressive Disorder (MDD).

Table 1 lists some devices that are FDA cleared for major depressive disorder (Product Code: OBP), migraine headache pain (Product Code: OKP), and obsessive-compulsive disorder (Product Code: QCI).

Table 1. Repetitive Transcranial Magnetic Stimulation Devices Cleared by the U.S. Food and Drug Administration for Major Depression, Migraine, or Obsessive-Compulsive Disorder

Device	Manufacturer	Indication	FDA Clearance No.	FDA Clearance Date
Savi Dual™ Migraine Therapy	ENeura	Migraine (acute and prophylactic treatment in individuals ≥12 years of age)	K230358	05/16/2023
NeuroStar Advanced Therapy System	Neuronetics	Major Depressive Disorder	K231926	3/22/2024
Horizon 3.0 TMS Therapy System	Magstim	Major depressive disorder and obsessive-compulsive disorder	K222171	01/13/2023
ALTMS Magnetic Stimulation Therapy System	REMED Co., Ltd	Major Depressive Disorder	K220625	04/06/2022
Neurostar	Neuronetics	Major Depressive Disorder	K083538	12/16/2008
Brainsway Deep TMS System	Brainsway	Major Depressive Disorder	K122288	01/07/2013
		Obsessive-Compulsive Disorder	K183303	03/08/2019
Springtms Total Migraine System	Eneura	Migraine headache with aura	K140094	05/21/2014
Rapid Therapy System	Magstim	Major Depressive Disorder	K143531	05/08/2015
Magvita	Tonica Elektronik	Major Depressive Disorder	K150641	07/31/2015

Mag Vita TMS Therapy System w/Theta Burst Stimulation	Tonica Elektronik	Major Depressive Disorder	K173620	8/14/2018
Neurosoft	TeleEMG	Major Depressive Disorder	K160309	12/22/2016
Horizon	Magstim	Major Depressive Disorder	K171051	09/13/2017
Horizon TMS Therapy System (Theta Burst Protocol)	Magstim	Major Depressive Disorder	K182853	03/15/2019
Nexstim	Nexstim	Major Depressive Disorder	K171902	11/10/2017
Apollo	Mag & More	Major Depressive Disorder	K180313	05/04/2018

Medical Policy Statement

Transcranial magnetic stimulation of the brain has been established. It may be a useful treatment option in specified situations.

Inclusionary and Exclusionary Guidelines

Inclusions:

Transcranial magnetic stimulation therapy should be ordered by a board-certified psychiatrist, upon completion of a comprehensive evaluation.

MAJOR DEPRESSIVE DISORDER

Transcranial magnetic stimulation must be administered by an approved U.S. Food & Drug Administration (FDA) cleared device for the treatment of major depressive disorder (MDD), and modalities may include conventional TMS, deep TMS and theta burst stimulation. Specified stimulation parameters as follows: 5 days a week for 6 weeks followed by 6 more sessions over the subsequent two-week period as a taper from the initial phase of treatment (totaling 36 sessions); however the treatment plan can be individualized depending on the type of device used, safety and side effect considerations and response to treatment.

Must meet **all**:

1. The member is 15 to 70 years of age (includes ages 15 and 70).
2. A drug screen is obtained if indicated by history, current clinical evaluation, or a high degree of clinical suspicion.
3. A confirmed diagnosis of severe major depressive disorder (single or recurrent episode) measured by evidence-based scales such as Beck Depression Inventory (score 30-63), Zung Self-Rating Depression Scale (>70), PHQ-9 (>20), Hamilton Depression Rating Scale (>20), or Montgomery-Asberg Depression Rating Scale (MADRS) (score >34).

4. At least one of the following:

- The individual has tried and had an inadequate response to 2 antidepressant agents from 2 different antidepressant classes (i.e., selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, bupropion, or mirtazapine). An adequate trial of an antidepressant is defined by BOTH of the following:
 1. The trial length was at least 6 weeks at generally accepted doses or of sufficient duration as determined by the treating physician at the generally accepted doses; AND
 2. Individual was $\geq 80\%$ adherent to the agent during the trial.
- The individual is unable to tolerate a therapeutic dose of medications. Intolerance is defined as severe somatic or psychological symptoms that cannot be modulated by any means including but not limited to additional medications to ameliorate side effects. Examples of somatic side effects: persistent electrolyte imbalance, pancytopenia, severe weight loss, poorly controlled metabolic syndrome or diabetes.

Examples of psychological side effects: suicidal-homicidal thinking/attempts, impulse dyscontrol.

Note: A trial of less than one week of a medication is not considered a qualifying trial to establish intolerance.

- The individual has a history of response to TMS in a previous depressive episode (and it has been at least 3 months since the prior episode)
 - The individual is a candidate for electroconvulsive therapy; further, electroconvulsive therapy would not be clinically superior to transcranial magnetic stimulation (eg, in cases with psychosis, acute suicidal risk, catatonia or life-threatening inanition TMS should NOT be utilized).
5. The individual failed a trial of an evidence-based psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration without significant improvement in depressive symptoms as documented by standardized rating scales that reliably measure depressive symptoms (eg, Becks Depression Inventory, Zung Self-Rating Depression Scale, PHQ-9, Hamilton Depression Rating Scale, or MADRS).

OBSESSIVE-COMPULSIVE DISORDER (OCD)

Transcranial magnetic stimulation must be administered by an approved U.S. Food & Drug Administration (FDA) cleared device for the treatment of obsessive-compulsive disorder (OCD), and modalities may include conventional TMS, deep TMS and theta burst stimulation. Specified stimulation parameters as follows: 5 days a week for 6 weeks followed by 6 more sessions over the subsequent two-week period as a taper from the initial phase of treatment (totaling 36 sessions). Individual consideration may be extended to patients based on review of applicable medical records for refractory OCD defined as two therapeutic trials of medications and psychotherapy with one augmentation episode that has failed.

Conditions that must be met during the entire TMS treatment:

- The treatment must be administered by a board-certified psychiatrist trained in TMS therapy; or a trained technician, under the supervision of a board-certified psychiatrist trained in TMS therapy.
- An attendant trained in: BCLS, the management of complications (such as seizures), and the use of appropriate equipment, must be present.
- Adequate resuscitation equipment must be available (eg, suction and oxygen).
- The facility must maintain awareness of response times of emergency services (either fire/ambulance or “code team”), which should be available within five minutes. These relationships are reviewed at least once per year and include mock drills.

Exclusions:

- All other behavioral health, neuropsychiatric or medical conditions (eg, anxiety disorders, mood disorders, schizophrenia, Alzheimer’s, dysphagia, seizures, migraine headaches, etc.)
- Pregnancy
- Maintenance treatment
- Presence of psychosis in the current episode
- Seizure disorder or any history of seizure, except those induced by ECT or isolated febrile seizures in infancy without subsequent treatment or recurrence
- Presence of an implanted magnetic-sensitive medical device located less than or equal to 30 centimeters from the TMS magnetic coil or other implanted metal items, including but not limited to a cochlear implant, implanted cardioverter defibrillator, pacemaker, vagus nerve stimulator, or metal aneurysm clips or coils, staples, or stents

Note: Dental amalgam fillings are not affected by the magnetic field and are acceptable for use with TMS.

- If the patient (or, when indicated, the legal guardian) is unable to understand the risk and benefits of TMS and provide informed consent
- Presence of a medical or co-morbid psychiatric contraindication to TMS
- Patient lacks a suitable environmental, or social and/or professional support system for post-treatment recovery
- There is not a reasonable expectation that the patient will be able to adhere to post-procedure recommendations

Note: Caution should be exercised in any situation where the patient’s seizure threshold may be decreased. Examples include:

- Presence in the bloodstream of a variety of agents, including but not limited to tricyclic antidepressants, clozapine, antivirals, theophylline, amphetamines, PCP, MDMA, alcohol, cocaine as these present a significant risk
- Presence of the following agents, including but not limited to SSRIs, SNRIs, bupropion, some antipsychotics, chloroquine, some antibiotics, some chemotherapeutic agents as they present a RELATIVE risk and should be considered when making risk-benefit assessments
- Withdrawal from alcohol, benzodiazepines, barbiturates and chloral hydrate also present a strong relative hazard

CPT/HCPCS Level II Codes *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure.)*

Established codes:

90867 90868 90869 0858T

Other codes (investigational, not medically necessary, etc.):

N/A

Note: Individual policy criteria determine the coverage status of the CPT/HCPCS code(s) on this policy. Codes listed in this policy may have different coverage positions (such as established or experimental/investigational) in other medical policies.

Rationale

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, two domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

TREATMENT-RESISTANT DEPRESSION

Clinical Context and Test Purpose

The purpose of repetitive transcranial magnetic stimulation (rTMS) is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with treatment-resistant depression (TRD).

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with treatment-resistant depression.

Interventions

The therapy being considered is rTMS.

Comparators

The following therapies are currently being used to treat TRD: pharmacotherapy, psychological and behavioral therapy, and electroconvulsive therapy (ECT).

Outcomes

The general outcomes of interest are reductions in symptoms and improvements in quality of life and functional outcomes.

Table 2. Health Outcome Measures Relevant to Treatment-Resistant Depression, Major Depressive Disorder, Suicidal Ideation, and Suicidal Behavior

Outcome	Description	Scale	Clinically Meaningful Difference
MADRS	Physician scored Rates presence and severity of depression Symptom domains include sadness; pessimism; inability to feel; suicidality	Contains 10 items (scored from 0 to 6) with higher scores indicating more severe depression No validated cut-off score but generally 0 to 6 normal (no depression); 7 to 19 mild depression; 20 to 34 moderate depression; 35 to 59 severe depression; 60 or greater very severe depression ¹ ,	No consensus to define remission. Thresholds for remission have ranged from 6 to 12 in trials. One literature review reported that the mean weighted MADRS score for remission was 4.0 (95% CI, 3.5-4.5) based on 10 studies. ² The definition of remission was a complete absence of clinically significant symptoms of depression. As per FDA, for drugs that have been approved to treat MDD as monotherapy or adjunctive treatment, treatment differences were typically closer to 3 or 4 points in MADRS scores. The observed treatment differences in esketamine studies were in that range. ³

HAM-D	<p>Physician scored Rates presence and severity of depression Used in a number of registration studies of approved oral antidepressants Symptom domains include sadness; pessimism; inability to feel; suicidality</p>	<p>There are 2 versions: 17 or 25 items; 17 items is more common Each item scored in a range of 0 to 2 or 0 to 4, with higher scores indicating a greater degree of depression Scores range from 0 to 48 Scores as low as 17 are associated with moderate depression and those at or above 24 are associated with severe depression^{2,}</p>	<p>Remission is defined as total score of 7 or less. But 2 or less has been suggested as optimal. Response to treatment is defined as a 50% reduction from baseline scores.</p>
SIBAT	<p>Contains both patient- and clinician-reported modules and can be assessed by patient or rated by the physician Includes assessments of Severity of Suicidality (CGI-SS-r) Imminent Suicide Risk (CGI-SR-I) Frequency of Suicidal Thinking (FoST)⁴.</p>	<p>CGI-SS-r: rated from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal patients) CGI-SR-I: rates best clinical judgment of participant's imminent risk for suicide within the next 7 days. Scale indicates: 0 (No imminent suicide risk), 1 (Minimal imminent), 2 (Mild imminent), 3 (Moderate imminent), 4 (Marked imminent), 5 (Severely imminent), 6 (Extreme imminent). FoST: describes the clinician determined estimate of the frequency of the participant's suicidal thinking. Scored on a 6-point Likert scale: 0 (Never), 1 (Rarely), 2 (Sometimes), 3 (Often), 4 (Most of the time), 5 (All of the time).⁴.</p>	<p>No literature was identified for a consensus definition for a clinically meaningful change in scores</p>

CGI-SR-I: Clinical Global Impression of Imminent Suicide Risk Scale, CGI-SS-r: Clinical Global Impression of Severity of Suicidality-Revised, CI: confidence interval; FDA: U.S. Food and Drug Administration; FoST: Frequency of Suicidal Thinking, HAM-D: Hamilton Rating Scale for Depression, MADRS: Montgomery-Asberg Depression Rating Scale, MDD: major depressive disorder; SIBAT: Suicide Ideation and Behavior Assessment Tool.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess longer term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

REVIEW OF EVIDENCE

Evaluation of rTMS for (TRD) includes RCTs comparing rTMS with sham as well as evidence when used as a replacement for or adjunct to pharmacotherapy that has not improved depressive symptoms. In addition, evaluation of rTMS in TRD includes the use of rTMS as an alternative to ECT. However, some individuals may not want to use ECT due to its requirement for general anesthesia and induction of seizures.

There has been a trend to use rTMS at increased levels of intensity, trains of pulses, total pulses per session, and the number of sessions.⁵ Unless otherwise indicated, stimulation was set at 100% to 120% of motor threshold, clinical response was defined as an improvement of 50% or more on the Hamilton Rating Scale for Depression (HAM-D), and remission was considered to be a score of 7 or less on the HAM-D. Refer to the meta-analysis by Schutter (2009) for a summary of study characteristics and stimulation parameters used in trials conducted prior to 2008.⁶

Systematic Reviews

The Health Quality Ontario (2016) published a systematic review of left dorsolateral prefrontal cortex (DLPFC) rTMS for TRD.⁷ Reviewers included 23 RCTs (n=1156 patients) that compared rTMS with sham and 6 RCTs (n=266 patients) that compared rTMS with ECT. In 16 studies, patients received rTMS in addition to antidepressant medication. Seven studies used intensities of less than 100% motor threshold and the definition of remission in the included studies varied (from ≤ 7 to ≤ 10 on the HAM-D). Meta-analysis showed a statistically significant improvement in depression scores compared with sham, with a weighted mean difference (WMD) of 2.31 (Table 3). However, this was smaller than the prespecified clinically important difference of 3.5 points on the HAM-D, and the effect size was small (0.33; 95% confidence interval [CI], 0.17 to 0.5; $p < .001$). Subgroup analysis showed a larger and clinically significant treatment effect in the rTMS studies using 20 Hz with shorter train duration compared with other rTMS techniques (WMD=4.96; 95% CI, 1.15 to 8.76; $p = .011$). Secondary analyses showed rTMS demonstrated a statistically greater response rates among 20 studies (pooled relative risk, 1.72) as well as statistically greater remission rates among 13 studies (pooled relative risk, 2.20). For the 6 trials that compared rTMS with ECT, the WMD of 5.97 was both statistically and clinically significant in favor of ECT. The relative risk for remission and response rates are shown in Table 3, which while favoring ECT were not statistically significant. Remission and relapse rates at the 6-month follow-up were reported in 2 studies (n=40 and n=46 subjects) comparing rTMS with ECT. While 1 study reported a slightly higher remission rate for ECT (27.3%) than for rTMS (16.7%), the other study did not find a significant difference between ECT and rTMS for mean depression scores at 3 or 6 months, but did note

relapses were less frequent for ECT. Statistical comparisons were either not significant or not available, limiting the interpretation of these findings.

Table 3. Statistical Comparisons for Depression Scores After Repetitive Transcranial Magnetic Stimulation

Comparison	Favors	WMD (95% CI)	p	RR for Remission (95% CI)	p	RR for Response (95% CI)	p
rTMS vs sham	rTMS	2.31 (1.19 to 3.43)	<.001	2.20 (1.44 to 3.38)	.001	1.72 (1.13 to 2.62)	.01
rTMS vs ECT	ECT	5.97 (0.94 to 11.0)	.02	1.44 (0.64 to 3.23)	.38	1.72 (0.95 to 3.11)	.07

CI: confidence interval; ECT: electroconvulsive therapy; rTMS: repetitive transcranial magnetic stimulation; RR: relative risk; WMD: weighted mean difference.

Brunoni et al (2017) conducted a systematic review to compare different modalities of rTMS for TRD.⁸ Bilateral, high frequency rTMS, low-frequency rTMS, and theta burst stimulation were statistically significantly more effective than sham with respect to response (odds ratio [OR], 3.39; 95% CI, 1.91 to 6.02]; OR, 3.28 [95% CI, 2.33 to 4.61]; OR, 2.48 [95% CI, 1.22 to 5.05]; OR, 2.57 [95% CI, 1.17 to 5.62], respectively). In network meta-analysis, deep TMS was not more effective than sham TMS for response (OR 1.49 ; 95% CI 0.50 to 4.47) or remission (OR 2.45; 95% CI 0.74 to 8.07), but this result was based on only 1 RCT.

A systematic review conducted by Voigt et al (2021) focused on theta burst stimulation of TRD.⁹ The reviewers included 8 RCTs comparing theta burst stimulation to sham treatment and 1 comparing theta burst stimulation to conventional rTMS. As measured by the HAM-D, theta burst stimulation was superior to sham on response (RR 2.4; 95% CI: 1.27 to 4.55; p=.007; I² = 40%). There was no statistically significant difference between theta burst stimulation and conventional rTMS (RR 1.02; 95% CI: 0.85 to 1.23; p=.80; I² = 0%). There was no difference between theta burst stimulation and rTMS in the incidence of adverse events.

Randomized Controlled Trials

The ASCERTAIN-TRD study was a 3-arm, open-label study published by Papakostas et al (2024).⁶⁰ In this study, patients with TRD (failed ≥2 antidepressants) were randomized to augmentation with either aripiprazole or rTMS or were switched to venlafaxine XR. The study was open-label and limited to 8 weeks duration. A total of 235 individuals completed the study. MADRS response rates were numerically improved with rTMS augmentation compared with either aripiprazole augmentation or switching to venlafaxine/duloxetine (52.2% vs 38.1% and 35.8%, respectively). MADRS remission rates were also better among rTMS-treated individuals (34.2% vs 25.3% and 24.9%, respectively). MADRS score changes were significantly improved with rTMS (-17.39; p=.015) compared with switch (-13.22); however, augmentation with aripiprazole (-14.9; p=.069) was not significantly better than switch.

Theta Burst Stimulation Compared to Conventional Transcranial Magnetic Stimulation

Blumberger et al (2018) published a multicenter, randomized noninferiority trial Conventional Versus Theta Burst Repetitive Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder, comparing 10-Hz rTMS with intermittent theta burst stimulation (iTBS).¹⁰ Between 2013 and 2016, 414 patients with TRD were enrolled and randomized to 4 to 6 weeks of rTMS (n=205) or iTBS (n=209). Treatment resistance was defined as failure to tolerate two or more antidepressant trials of inadequate dose and duration or no clinical response to an adequate dose of an antidepressant. Patients who failed more than three antidepressant trials of adequate dosage were excluded from the trials. Patients could alter their medication during this trial. Treatment with conventional rTMS (37 minutes) and iTBS (3 minutes) was delivered 5 times a week for 4 to 6 weeks. The primary outcome measure was the 17-item HAM-D, for which scores for patients treated with rTMS improved by 10.1 points and scores for patients treated with iTBS improved by 10.2 points (adjusted difference, 0.103; lower 95% CI, -1.16; p=.001). Treatment with iTBS resulted in a higher self-rated intensity of pain (mean score, 3.8) than treatment with rTMS (mean score, 3.4; p=.011). Headache was the most common treatment-related adverse event for both groups (rTMS=64% [131/204]; iTBS=65% [136/208]). Serious adverse events were noted in patients treated with rTMS (one case of myocardial infarction) and iTBS (one case each of agitation, worsening suicidal ideation, worsening depression); there was no significant difference in the number of adverse events in the two groups. The trial lacked a treatment group with placebo.

Deep Transcranial Magnetic Stimulation

The RCT leading to 510(k) clearance of the Brainsway Deep TMS System in 2013 was conducted at 20 centers across the United States (n=13), Israel (n=4), Germany (n=2), and Canada (n=1).¹¹ The trial included 229 patients with major depressive disorder who had not received benefit from 1 to 4 antidepressant trials or were intolerant of at least 2 antidepressant treatments. Using per-protocol analysis, which excluded 31 patients who did not receive adequate TMS treatment and 17 patients who did not meet the inclusion and exclusion criteria, the RCT showed a significant benefit for both response rate (38.4% vs 21.4%) and remission rate (32.6% vs 14.6%). Modified intention-to-treat analysis (ITT), which excluded the 17 patients not meeting selection criteria, showed a significant benefit in both response rate (37% vs 22.8%) and remission rate (30.4% vs 15.8%). At the end of the maintenance period (16-week follow-up), the response rate remained significantly improved for deep TMS. Remission rates were not reported. The ITT analysis found no significant benefit of treatment at 4 or 16 weeks.

Durability of Conventional Transcranial Magnetic Stimulation

Systematic Reviews

Kedzior et al (2015) examined the durability of the antidepressant effect of high-frequency rTMS of the left DLPFC in the absence of maintenance treatment.¹² Included were 16 double-blind, sham-controlled randomized trials (N=495). The range of follow-up was 1 to 16 weeks, but most studies only reported follow-up to 2 weeks. The overall effect size was small with a standardized mean difference (SMD; Cohen's *d*) of -0.48, and the effect sizes were lower in RCTs with 8 to 16 weeks of follow-up (*d*= -0.42) than with 1 to 4 weeks of follow-up (*d*= -0.54). The effect size was higher when an antidepressant medication was initiated concurrently with rTMS (5 RCTs, *d*= -0.56) than when patients were on a stable dose of medication (9 RCTs, *d*= -0.43) or were unmedicated (2 RCTs, *d*= -0.26).

Observational Studies

Dunner et al (2014) reported a 1-year follow-up with maintenance therapy from a large multicenter observational study (42 sites) of rTMS for patients with TRD.¹³ A total of 257 patients agreed to participate in the follow-up study of 307 who were initially treated with rTMS. Of these, 205 completed the 12-month follow-up, and 120 patients had met the Inventory of Depressive Symptoms-Self Report response or remission criteria at the end of treatment. Ninety-three (36.2%) of the 257 patients who enrolled in the follow-up study received additional rTMS (mean, 16.2 sessions). Seventy-five (62.5%) of the 120 patients who met response or remission criteria at the end of the initial treatment phase (including a 2 month taper phase) continued to meet response criteria through 1-year follow-up.

A variety of tapering schedules are being studied. Richieri et al (2013) used propensity-adjusted analysis of observational data and found that the group of patients who had maintenance rTMS tapered over 20 weeks (from 3 times per week to once a month) had a significantly reduced relapse rate compared with patients who had no additional treatment (37.8% vs 81.8%).¹⁴ Connolly et al (2012) reported that in the first 100 cases treated at their institution, the response rate was 50.6% and the remission rate was 24.7%.¹⁵ At 6 months after the initial rTMS treatment, 26 (62%) of 42 patients who received tapered maintenance therapy (from 2 sessions per week for the first 3 weeks to monthly) maintained their response. In another study, Janiack et al (2010) evaluated patients who met criteria for partial response during either a sham-controlled or open-label phase of a prior study and were tapered from rTMS and simultaneously started on maintenance antidepressant monotherapy.¹⁶ During the 24-week follow-up, 10 of 99 patients relapsed, 38 had symptom worsening, and of these 32 (84%) had symptomatic benefit with adjunctive rTMS.

Section Summary: Treatment-Resistant Depression

There are a large number of sham-controlled randomized trials and meta-analyses of these RCTs on rTMS for depression. Meta-analyses found improved response rates and rates of remission for conventional rTMS and theta burst stimulation compared with sham TMS. Additionally, a head-to-head trial showed noninferiority of theta burst stimulation to conventional rTMS, with no difference in the incidence of adverse events. There is some evidence that rTMS, when given in conjunction with the initiation of pharmacologic therapy, improves the response rate compared with pharmacologic therapy alone, while the effect of rTMS is less robust when it is given in combination with a stable dose of antidepressant medication. There is limited evidence to compare the effects of these treatments on cognition, although the adverse effects of rTMS appear to be minimal. While the most recent meta-analyses have found that the effect of rTMS is smaller than the effect of ECT on TRD, given that rTMS does not require general anesthesia or induce seizures and some individuals may not elect ECT, the balance of incremental benefits and harms associated with rTMS may be reasonable compared with ECT.

MIGRAINE HEADACHE

Clinical Context and Therapy Purpose

The purpose of rTMS is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with migraine headache pain.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with migraine headaches.

Interventions

The therapy being considered is rTMS.

Comparators

The following therapies are currently being used to treat migraine headache pain: pharmacotherapy (e.g., triptans, ibuprofen, combination analgesics).

Outcomes

The general outcomes of interest are reductions in symptoms and improvements in QOL and functional outcomes.

Study Selection Criteria

Previously stated under the first indication.

Review of Evidence

Systematic Review

Saltychev et al (2022) conducted a systematic review and meta-analysis of 8 RCTs that compared rTMS to sham stimulation in patients with migraine. ¹⁷, All RCTs used high-frequency rTMS to the left dorsolateral prefrontal cortex and all studies except 1 included patients with chronic migraine. All studies except 1 had a low risk of bias and the risk of publication bias was nonsignificant. Results for the frequency of migraine days per month and the intensity of migraine pain both favored rTMS; however, the authors stated that the difference in migraine pain intensity was clinically insignificant. The analysis is summarized in Tables 4 and 5.

Table 4. Systematic Review & Meta-Analysis Characteristics

Study	Dates	Trials	Participants	N (Range)	Design	Duration
Saltychev et al (2022) ¹⁷	2004-2021	8	Adults with migraine	339 (11 to 100)	RCTs	3 to 12 rTMS sessions over 3 days to 8 weeks

Table 5. Systematic Review & Meta-Analysis Results

Study	Migraine days per month	Migraine pain (scale of 0 to 100)
Saltychev et al (2022) ¹⁷		
N=339	N=339	N=257
Difference (95% CI)	-8.09 (-11.4 to -4.79)	-13.56 (-21.8 to -5.32)
I^2	$I^2=87%$	$I^2=86%$

CI: confidence interval

Randomized Controlled Trial

A pivotal randomized, double-blind, multicenter, sham-controlled trial was performed with the Cerena TMS device to demonstrate the safety and effectiveness of a de novo application.¹⁸ Enrolled in the trial were 201 patients with a history of an aura preceding more than 30% of headaches of moderate or severe, severity for approximately 90% of migraine attacks. Following a month-long baseline phase to establish the frequency and severity of the migraine, patients were randomized to a treatment phase consisting of 3 treatments or 3 months, whichever occurred first. Patients were instructed to treat their migraine headache during the aura phase and to record their pain severity (0-3), severity of associated migraine symptoms (photophobia, phonophobia, nausea), presence of vomiting, and use of rescue medications at the time of treatment and at 1, 2, 24, and 48 hours after treatment. The primary endpoint was the proportion of patients who were pain-free 2 hours after treatment. Of the 201 patients enrolled, 164 recorded at least 1 treatment and 113 recorded at least 1 treatment when there was pain. Post hoc analysis of these 113 patients showed a benefit of the device for the primary endpoint (37.74% pain free after 2 hours for Cerena vs 16.67% for sham, $p=.018$) and for the proportion of subjects who were pain free after 24 hours (33.96% for Cerena vs 10% for sham; $p=.002$). Active treatment was not inferior to sham for the proportion of subjects free of photophobia, suggesting that the device does not worsen photophobia. However, the device was not inferior to sham for the proportion of subjects free of nausea and phonophobia.

Section Summary: Migraine Headache

There is little evidence on the use of TMS devices to treat a migraine headache. The results of the pivotal trial were limited by the 46% dropout rate and post hoc analysis. According to the Food & Drug Administration (FDA) labeling, the device has not been demonstrated as safe or effective when treating cluster headache, chronic migraine headache, or migraine headache during the aura phase. The device has not been demonstrated to be as effective in relieving the associated symptoms of migraine (photophobia, phonophobia, nausea).¹⁸

OBSESSIVE-COMPULSIVE DISORDER

Clinical Context and Therapy Purpose

The purpose of rTMS is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with obsessive-compulsive disorder (OCD).

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with OCD.

OCD is characterized by the inability to suppress intrusive thoughts, impulses, images, and repetitive motor responses.

Interventions

The therapy being considered is rTMS.

The use of TMS for patients with OCD is based on the observation that OCD symptoms are associated with excessive activity in certain cortical areas. TMS is proposed as a treatment to modulate these brain areas.

Comparators

The following therapies are currently being used to treat OCD: pharmacotherapy, psychological and behavioral therapy.

Outcomes

The general outcomes of interest are reductions in symptoms and improvements in quality of life and functional outcomes.

The Yale-Brown Obsessive Compulsive Scale (YBOCS) is a clinician-rated, 10-item scale commonly used to assess the severity of symptoms in OCD.¹⁹ Each item is rated from 0 (no symptoms) to 4 (extreme symptoms) (total range, 0 to 40), with separate subtotals for the severity of obsessions and compulsions.

YBOCS scores of 0-13 correspond to 'mild symptoms' on the Clinical Global Impression of Severity (CGI-Severity=0-2), 14-25 with 'moderate symptoms' (CGI-Severity=3), 26-34 with 'moderate-severe symptoms' (CGI-Severity=4) and 35-40 with 'severe symptoms' (CGI-Severity=5-6).²⁰ An improvement of $\geq 35\%$ on the YBOCS is most predictive of treatment response.²¹

Follow-up over months is of interest to monitor outcomes.

Study Selection Criteria

Previously stated under the first indication.

REVIEW OF EVIDENCE

Systematic Reviews

A systematic review by Trevizol et al (2016) included 15 RCTs (N=483) that compared active with sham rTMS for OCD (Tables 3 and 4).²² All studies were sham-controlled and double-blinded. The sample sizes in the trials ranged from 18 to 65 patients. Seven studies used low-frequency stimulation and eight studies used high-frequency stimulation. The cortical regions varied among the studies, targeting the supplementary motor area, orbitofrontal cortex, or left, right, or bilateral DLPFC. The researchers calculated the standardized mean difference for the primary outcome (YBOCS score). Response rates were not reported.

The pooled mean difference between groups on the YBOCS was 2.94 (95% CI, 1.26 to 4.62), translating to a small to moderate effect size for active stimulation of 0.45 (95% CI, 0.20 to 0.71). Individual adverse effects were not assessed due to a lack of reporting in the primary studies, but there was no difference between groups in the dropout rate. Intervention protocols were heterogeneous across the studies, but regression analysis did not identify any treatment protocol or other variables as predictors of TMS response.

More recently, Liang et al (2021) conducted a systematic review and meta-analysis of different TMS modalities for the treatment of OCD.²³ Three of the 5 protocols assessed were significantly more efficacious than sham TMS, and all treatment strategies were similar to sham TMS regarding tolerability (Table 3). Transcranial magnetic stimulation was not more effective than sham TMS, but there was direct evidence from only 1 RCT for this comparison

(Carmi et al, 2019, discussed in the next section).²⁴ The overall quality of the evidence was rated very low for efficacy and low for tolerability, and the reviewers concluded that high quality RCTs with low selection and performance bias are needed to further verify the efficacy of specific rTMS strategies for OCD treatment.

Perera et al (2021) conducted a systematic review and meta-analysis of rTMS in the treatment of OCD.²⁵ All RCTs in the analysis (n=26) had a low risk of bias. A random effects model was used to compare pre- and post-stimulation YBOCS scores, with effect sizes reported as Hedges' *g*. The analysis found that rTMS had a significant effect on YBOCS scores compared to sham (effect size, 0.64; 95% CI, 0.39 to 0.89; $p < .0001$). Raw mean difference in YBOCS score between treatments was 4.04 (95% CI, 2.54 to 5.54; $p < .001$). The effect size was still significant when 2 dominant trials were removed. Effect sizes with rTMS appeared to be significant until 4 weeks after treatment, and low- and high-frequency rTMS had similar efficacy to each other. The authors performed several subgroup analyses (cortical target, stimulation frequency, total pulses per session, total duration of treatment) but none of the effect sizes were significant between rTMS and sham.

Table 6. Systematic Review of TMS in Patients with OCD-Characteristics

Study	Dates	Trials Included	Participants	N (Range)	Design	Duration
Perera et al (2021) ²⁵ .	Up to October 2020	26	Mean age, 33 years	781	RCT, sham-controlled	1 week to 6 weeks
Liang et al (2021) ²³ .	Up to March 2020	22	Mean age, 34.1 years	698	RCT, sham- or active-controlled	1 week to 10 weeks
Trevizol et al (2016) ²² .	Up to March 2016	15	Mean age, 31.9 (SD, 7.6) years, 44.1% women	483 (18 to 65); mean, 16.1 (SD, 8.45)	RCT, sham-controlled	1 week to 6 weeks

OCD: obsessive-compulsive disorder; RCT: randomized controlled trial; SD: standard deviation; TMS: transcranial magnetic stimulation.

Table 7. Systematic Review and Meta-Analysis: Results

Study	YBOCS Score	Dropouts
Perera et al (2021) ²⁵ .		
Total N	781	781
	Mean difference (95% CI)	
Active rTMS	4.04 (2.54 to 5.54)	NR
	$I^2=62.06%$; $p < .0001$	
Liang et al (2021) ²³ .		
	Mean Difference (95% CrI)	OR (95% CrI)

Low frequency rTMS applied over the dorsolateral prefrontal cortex	6.34 (2.12 to 10.42)	0.81 (0.08 to 8.17)
High-frequency rTMS applied over the dorsolateral prefrontal cortex	3.75 (1.04 to 6.81)	1.08 (0.37 to 3.19)
Low-frequency rTMS applied over the supplementary motor area	4.18 (0.83 to 7.62)	0.98 (0.37 to 2.67)
Low-frequency rTMS applied over the orbitofrontal cortex	4.43 (-2.57 to 11.31)	0.59 (0.06 to 5.68)
High-frequency rTMS applied over the anterior cingulate cortex/medial prefrontal cortex (deep TMS)	4.25 (-1.16 to 9.59)	1.62 (0.26 to 15.98)
Trevizol et al (2016) ²² .		
Total N	483	483
	SMD: 0.45 (0.20 to 0.71)	OR: 1.02 (0.76 to 1.36)
	$I^2=43%$; $p=.039$	
	Mean Difference: 2.94 (1.26 to 4.62)	
	$I^2=58%$; $p=.002$	

CrI: credible interval; OR: odds ratio; rTMS: repetitive transcranial magnetic stimulation; SMD: standardized mean difference; YBOCS: Yale-Brown Obsessive-Compulsive Scale.

Randomized Controlled Trial

This section discusses in detail the sham-controlled RCT of deep TMS for OCD conducted by Carmi et al (2019).²⁴ The trial was submitted to the FDA as part of the de novo classification request, to establish a reasonable assurance of safety and effectiveness of the device.²⁶ Study characteristics and results are summarized in Tables 8 and 9, and limitations are shown in Tables 10 and 11. A total of 99 patients were randomized to active treatment or sham. The primary outcome was the difference between groups in the mean change from baseline to six weeks on the YBOCS. Secondary outcomes included the response rate (defined as a 30% or greater improvement from baseline on the YBOCS), the Clinical Global Impression of Improvement (CGI-I), the CGI-S and the Sheehan Disability Scale, a patient-reported measure of disability and impairment. Results at 10 weeks were also reported as secondary outcomes.

The primary efficacy analysis used a modified ITT analysis (n=94), excluding 5 patients who were found to not meet eligibility criteria following randomization. There was a greater decrease from baseline in the active treatment group (-6.0 points) than the sham group (-2.8 points), translating to a moderate effect size of 0.69. At 6 weeks, the response rate was 38.1% in the active treatment group compared to 11.1% in the sham group (P=0.003). The FDA review provides data from the ITT analysis of the mean change in the YBOCS score (n=99). In the ITT data set, the YBOCS score decreased by -6.0 points (95% CI, -3.8 to -8.2) in the active group and by -4.1 points (95% CI, -1.9 to -6.2) in the sham group. Although the

decreases were both statistically significant from baseline, the difference of 1.9 points between the treatment arms was not statistically significant ($p=.0988$). Results on the secondary outcomes were mixed. More patients in the active treatment group were considered improved based on the Clinical Global Impression of Improvement and the CGI-S at 6 weeks, but there was no significant difference between groups on the Sheehan Disability Scale (Table 6).

Table 8. Summary of Key Randomized Controlled Trial Characteristics - Transcranial Magnetic Stimulation for Patients with Obsessive-Compulsive Disorder

Study; Trial	Countries	Sites	Dates	Participants	Interventions	Duration of follow-up
Carmi et al (2019) ²⁴ NCT02229903	U.S., Israel, Canada	11	2014-2017	N=99 adults ages 22-68 years, diagnosis of OCD as a primary disorder, receiving treatment in an outpatient setting, and have a YBOCS score >20; in maintenance treatment with a therapeutic dosage of a serotonin reuptake inhibitor (SRI) for at least 2 months before randomization or, if they were not on an SRI, in maintenance treatment on cognitive behavioral therapy (CBT) and have failed to respond adequately to at least one past trial of an SRI. Exclusions: primary axis I diagnosis other than OCD, severe neurological impairment, any condition associated with an increased risk of seizures.	Deep TMS 6-week treatment phase (consisting of 5 weeks of daily treatments 5 days a week and four treatments during the 6th week)	Sham 6 weeks (primary) 10 weeks (secondary)

CBT: cognitive behavior therapy; OCD: obsessive-compulsive disorder; SRI: serotonin reuptake inhibitor; TMS: transcranial magnetic stimulation; YBOCS: Yale-Brown Obsessive-Compulsive Scale.

Table 9. Summary of Key Randomized Controlled Trial Results - Transcranial Magnetic Stimulation for Patients with Obsessive-Compulsive Disorder

Study	YBOCS (Primary Outcome)	YBOCS Response	CGI-I	CGI-S (modified)	Sheehan Disability Scale	Adverse events (all)	Dropouts
Carmi et al (2019) ²⁴ NCT02229903	Mean change from baseline at 6 weeks	(≥30% change from baseline to 6 weeks)	Moderate to very much improved from baseline at 6 weeks				
N analyzed	94	94	94	94			
TMS	-6.0 points (95% CI=4.0, 8.1)	38.1% (16/42),	20/41 (49%)	25/41 (61%)	-3.8 points (95% CI -1.5, -6.1)	73%	6/48 (12.5%)
Sham	-3.3 points (95% CI=1.2, 5.3)	11.1% (5/45)	9/43 (21%)	14/43 (32.6%)	-3.0 points (95% CI -0.8, -5.3)	69%	6/51 (12.0%)

Difference; P-value	2.8 points; p=.01 Effect size: 0.69	p=.003	p=.011	p=.022	NS (p-value not reported)	p=.639	NS (p-value not reported)
---------------------	--	--------	--------	--------	---------------------------	--------	---------------------------

CGI-I: Clinical Global Impression of Improvement; CGI-S: Clinical Global Impression of Severity; CI: confidence interval; NS: non-significant; TMS: transcranial magnetic stimulation; YBOCS: Yale-Brown Obsessive-Compulsive Scale.

Table 10. Study Relevance Limitations

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Follow-Up ^e
Carmi et al (2019) ²⁴ NCT02229903					1,2. 6 weeks (primary)

The study limitations stated in this table are those notable in the current review; this is not a comprehensive limitations assessment.

a Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5. Other.

c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.

d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. Incomplete reporting of harms; 4. Not establish and validated measurements; 5. Clinically significant difference not prespecified; 6. Clinically significant difference not supported; 7. Other.

e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

Table 11. Study Design and Conduct Limitations

Study	Allocation ^a	Blinding ^b	Selective Reporting ^c	Data Completeness ^d	Power ^e	Statistical ^f
Carmi et al (2019) ²⁴ NCT02229903				6. Modified ITT analysis of 94/100 patients who were enrolled. The difference in the primary outcome was not statistically significant in the ITT data set (n=99)		

ITT: intention-to-treat; NCT: national clinical trial.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive limitations assessment.

a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

Section Summary: Obsessive-Compulsive Disorder

The evidence on rTMS for OCD includes a number of small-to-moderate sized, sham-controlled, double-blind randomized trials and meta-analyses of these RCTs. A meta-analysis of 15 RCTs (N=483 patients, range 18 to 65 patients) conducted in 2016 found a benefit of rTMS on patient-reported OCD symptom severity at time points ranging from 2 to 6 weeks, but there was substantial variability in the stimulation parameters, including the cortical region that was stimulated and the frequency of stimulation. The largest meta-analysis conducted in 2021 included 26 RCTs. Differences in pre- and posttreatment YBOCS scores were significantly improved with rTMS compared to sham, but the evidence was only sufficient to conclude that the effects lasted until 4 weeks after the last treatment. In a network meta-analysis that included both direct and indirect evidence, the authors did not find that deep TMS was more effective than sham rTMS. The RCT that was the basis of FDA clearance of deep TMS for treatment of OCD compared deep rTMS to sham in 99 patients for 6 weeks, with an additional 4 weeks of follow-up as a secondary outcome. Using a modified intention-to-treat (ITT) analysis (n=94), there was a larger mean decrease from baseline (improvement) on the YBOCS score (the primary efficacy outcome) in the active treatment group (-6.0 points) than the sham group (-2.8 points), translating to a moderate effect size of 0.69. At 6 weeks, the response rate was 38.1% in the active treatment group compared to 11.1% in the sham group (p=.003), as measured by a 30% or greater increase in the YBOCS. The difference in the primary outcome measure between active and sham groups was not statistically significant in the ITT analysis. There was a benefit for rTMS on clinician-reported measures of improvement.

PSYCHIATRIC DISORDERS OTHER THAN DEPRESSION OR OBSESSIVE-COMPULSIVE DISORDER

Clinical Context and Therapy Purpose

The purpose of rTMS is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with psychiatric disorders other than depression or OCD.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with psychiatric disorders other than depression or OCD.

Interventions

The therapy being considered is rTMS.

Comparators

The following therapies are currently being used to treat psychiatric disorders other than depression or OCD: pharmacotherapy or psychological and behavioral therapy.

Outcomes

The general outcomes of interest are reductions in symptoms and improvements in QOL and functional outcomes.

Follow-up over months is of interest to monitor outcomes.

Study Selection Criteria

Previously stated under the first indication.

Review of Evidence

Bipolar Disorder

Systematic Review

Konstantinou et al (2022) conducted a systematic review of 31 RCTs of rTMS for the treatment of bipolar disorder; meta-analysis was not performed.²⁷ Most included studies were in the setting of bipolar depression (n=24). Only 8 studies had a low risk of bias. Overall, rTMS seems safe and well-tolerated but efficacy results are mixed and there is no consensus about the optimal rTMS regimen. The authors noted limitations of the available literature including heterogeneity among studies, differences in sham treatments, and small sample sizes. They also stated that adequately powered sham-controlled studies are needed to verify the efficacy of rTMS in patients with bipolar disorder.

Tee et al (2020) conducted a systematic review and meta-analysis of sham-controlled RCTs of rTMS for the treatment of bipolar disorder.²⁸ Eight trials of rTMS in bipolar depression showed small but statistically significant improvements in depression scores compared to sham control (standardized mean difference = 0.302, $p < .05$). However, most studies had a high risk of bias which could have exaggerated the treatment effects. The effect of rTMS was inconclusive in bipolar mania due to the high heterogeneity and limited number of controlled trials.

Generalized Anxiety Disorder

Systematic Review

Cui et al (2019) included 21 studies (N=1481 patients) in a meta-analysis of rTMS plus drug therapy compared to drug therapy alone for the treatment of generalized anxiety disorder.²⁹ Results of the analysis showed that rTMS improved anxiety symptoms as measured by the Hamilton Anxiety Scale, (standardized mean difference = -0.68, 95% CI -0.89 to -0.46). The conclusions that could be drawn from the body of evidence were limited by significant heterogeneity across studies, and the authors concluded that additional high-quality studies are needed to confirm the results.

Panic Disorder

Systematic Review

A Cochrane review by Li et al (2014) identified 2 RCTs (N=40) that compared low-frequency rTMS with sham rTMS over the right dorsolateral prefrontal cortex.³⁰ The larger of the 2 studies was a randomized, double-blind, sham-controlled trial by Mantovani et al (2013) who assessed 21 patients with panic disorder and comorbid major depression.³¹ The response was defined as a 40% or greater decrease on the Panic Disorder Severity Scale and a 50% or greater decrease in HAMD scores. After 4 weeks of treatment, the response rate for panic was 50% with active rTMS and 8% with sham. The trial had a high-risk of attrition bias. The overall quality of evidence for the two trials was considered low, and the sample sizes were small, precluding certainty in the conclusions about the efficacy of rTMS for panic disorder.

Posttraumatic Stress Disorder

Systematic Review

Trevizol et al (2016) published a systematic review on the efficacy of low and high frequency rTMS for posttraumatic stress disorder.³² Five sham-controlled randomized trials (total n=118 patients) were included. Most trials used stimulation of the right DLPFC, though some delivered rTMS to the left DLPFC or bilaterally. Three trials used high frequency stimulation while 1 used low frequency stimulation and another compared high with low frequency stimulation; the percent motor threshold ranged from 80% to 120%. Some trials provided rTMS in combination with a scripted narrative of the traumatic event, and different posttraumatic stress disorder scales were used. In a meta-analysis, active rTMS was found to be superior to sham (SMD=0.74; 95% CI, 0.06 to 1.42), although heterogeneity across the trials was high.

Brown et al (2024) published a Cochrane systematic review of rTMS for posttraumatic stress disorder.⁶¹ The search was conducted through January 2023, and the authors identified 13 RCTs (N=577). Notably, 5 studies were conducted in the US, primarily enrolling white, male veterans. The authors found that rTMS probably makes little to no difference on posttraumatic stress disorder severity immediately following treatment (SMD, -0.14; 95% CI, -0.54 to 0.27; 3 studies, 99 participants; moderate-certainty evidence); however, there was significant heterogeneity amongst the studies.

Schizophrenia

Systematic Reviews

He et al (2017) published a meta-analysis of the effects of 1-Hz (low frequency) and 10-Hz (high frequency) rTMS for auditory hallucinations and negative symptoms of schizophrenia, respectively.³³ For 1-Hz rTMS, 13 studies were included. Compared with sham, the rTMS group showed greater improvement in auditory hallucinations (standard mean difference, -0.29; 95% CI, -0.57 to -0.01). However, significant heterogeneity across the studies was found ($p=.06$). In the 7 studies using 10-Hz rTMS, the overall effect size for improvement in negative symptoms was -0.41 (95% CI, -1.16 to -0.35); again, there was significant heterogeneity across studies ($p<.001$). The review was further limited by the small number of articles included and by the lack of original data for some studies.

A Cochrane review by Dougall et al (2015) selected 41 studies (N=1473).³⁴ Based on very low-quality evidence, there was a significant benefit of low- and high-frequency temporoparietal TMS compared with sham for the global state (7 RCTs) and positive symptoms (5 RCTs). For prefrontal rTMS compared with sham, the evidence on global state and cognitive state was of very low-quality and equivocal. Reviewers concluded that the evidence was insufficient to support or refute the use of TMS to treat symptoms of schizophrenia and, although some evidence suggested that temporoparietal TMS might improve certain symptoms (eg, auditory hallucinations, positive symptoms of schizophrenia), the results were not sufficiently robust to provide certainty.

Randomized Controlled Trials

Several additional small, single center RCTs of rTMS for the treatment of schizophrenia have been published since the systematic reviews described above (Tables 12 and 13).³⁵⁻³⁸ These studies were limited by their small sample sizes, very high loss to follow-up, and inadequate duration of follow-up (Tables 14 and 15). Due to these limitations, these studies do not provide sufficient evidence to draw conclusions about the effectiveness of the technology in patients with schizophrenia.

Table 12. Summary of Key Randomized Controlled Trial Characteristics

Study; Trial	Countries	Sites	Dates	Participants	Interventions ¹		Duration of follow-up
					Active	Comparator	
Zhu et al (2021) ³⁸	China	7	2017-2018	Inpatients ages 18 to 50 years with a diagnosis of schizophrenia per ICD-10 criteria who were right-handed and clinically stable for the past 3 months (N=32)	Intermittent theta burst stimulation over the cerebellum (3 pulses at 50 Hz repeated at a rate of 5 Hx for a total of 600 pulses administered 5 times a week (Monday to Friday) for 2 weeks (N=32)	Sham intermittent theta burst stimulation (N=)	24 weeks
Guan et al (2020) ³⁵	China	1	Not reported	Male patients ages 20 to 60 years with a DSM-IV diagnosis of schizophrenia and ≥5-year duration of illness.	20 Hz stimulus on left DLPFC 40 sessions, administered 5 times a week (Monday to Friday) for 8 weeks (N=28)	Sham rTMS (N=28)	8 weeks

Kumar et al (2020) 36 ,	India	1	Not reported	Patients who were right-handed, clinically diagnosed as having schizophrenia as per ICD-10 criteria for at least 1 year; on stable doses of medicines (if receiving) for the last 4 weeks, but continued to have significant negative symptoms. Excluded patients who had received rTMS treatment in the past for a similar condition, comorbid ICD-10 Axis I diagnosis, or Axis II Personality Disorder or any other exclusion criteria common to every TMS protocol.	Active rTMS: 20 sessions of high frequency rTMS per day (5 consecutive sessions per week for 4 weeks) at 20 Hz frequency (N=50)	Sham rTMS (N=50)	4 months
Zhuo et al (2019) 37 .	China	1	2013-2014	Adults ages 20 to 60 years with a DSM-IV diagnosis of schizophrenia; on a stable dose of antipsychotic medication for at least 1 month before study enrollment. Exclusions: DSM-IV-TR axis I disorder other than schizophrenia; history of epilepsy or seizure; significant or unstable neurologic disorder; cardiac pacemaker; previous brain injury or surgery; any metal clips, plates, or other metal items in the head; or substance dependency; or ECT within 3months.	Active rTMS: 20 treatment sessions on consecutive weekdays. 20 Hz rTMS applied to the left DLPFC (N=35)	Sham rTMS (N=35)	4 weeks

DLPFC: dorsolateral prefrontal cortex; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th edition; ECT: electroconvulsive therapy; ICD-10: International Classification of Disease, 10th edition; rTMS: repetitive transcranial magnetic stimulation.

Table 13. Summary of Key RCT Results

Study	Main Results
Zhu et al (2021) ³⁸ .	At 2, 6, 12, and 24 weeks after the end of treatment, PANSS negative symptom scores were significantly lower in the rTMS group compared to the sham group (p<.05). The effect of treatment on positive symptoms and PANSS total scores was not significant.
Guan et al (2020) ³⁵ .	At 2 weeks, 4 weeks, and 6 weeks, no significant differences in PANSS total score and sub scores between the sham and treatment groups. Immediate memory performance was higher in the rTMS group compared with the sham group at week 8 after covarying for education, age, and dose of drug. The improvement in immediate memory score was correlated with a decrease in the excitement factor score.
Kumar et al (2020) ³⁶ .	Total SANS score was reduced significantly after the intervention in both the active (60.6 ± 11.75 to 43.9 ± 12.67 ; p<.01) and sham (61.5 ± 13.69 to 50.5 ± 14.11 ; p<.01) groups. Post-intervention scores were significantly lower among the subjects who received active rTMS as compared to those who received sham.
Zhuo et al (2019) ³⁷ .	Significant decrease in negative symptoms but no significant improvement in cognition.

PANSS: Positive and Negative Syndrome Scale; rTMS: repetitive transcranial magnetic stimulation. SANS: Scale for Assessing Negative Symptoms in Schizophrenia

Table 14. Study Relevance Limitations

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Follow-Up ^e
Zhu et al (2021) ³⁸ .	4. Included inpatients only				
Guan et al (2020) ³⁵ .	4. Included men only				1. 8 weeks not sufficient to show durability of effects
Kumar et al (2020) ³⁶ .					
Zhuo et al (2019) ³⁷ .					1. 4 weeks not sufficient to show durability of effects

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

a Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5. Other.

c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.

d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. Incomplete reporting of harms; 4. Not establish and validated measurements; 5. Clinically significant difference not prespecified; 6. Clinically significant difference not supported; 7. Other.
 e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

Table 15. Study Design and Conduct Limitations

Study	Allocation ^a	Blinding ^b	Selective Reporting ^c	Data Completeness ^d	Power ^e	Statistical ^f
Zhu et al (2021) ³⁸ .					1. power calculation not reported	
Guan et al (2020) ³⁵ .				1. 15/56 (26.8%) patients discontinued	1. power calculation not reported	
Kumar et al (2020) ³⁶ .				1. 33% attrition (32% active and 38% sham)		
Zhuo et al (2019) ³⁷ .				1. 10/70 discontinued (14.3%)	1. power calculation not reported	

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment. a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias. b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician. c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication. d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials). e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference. f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

Substance Use Disorders and Craving

Systematic Review

Jansen et al (2013) reported on results from a meta-analysis evaluating the effect of rTMS and transcranial direct current stimulation of the DLPFC on substance dependence (alcohol, nicotine, cocaine, marijuana) or food craving.³⁹ Seventeen double-blind, sham-controlled trials that used high-frequency stimulation were analyzed. Thirteen studies stimulated the left DLPFC and seven studies stimulated the right DLPFC or both sides. Twelve of the studies gave only 1 or 2 sessions. The standardized effect size was 0.476 (95% CI, 0.316 to 0.636), indicating a medium effect size for active stimulation over sham for a reduction in craving. However, the studies were small (range, 9-48 patients) and there was significant heterogeneity in selected studies. No significant differences were found in the effectiveness of rTMS vs transcranial direct current stimulation, the different substances, or the side of stimulation, although this analysis might have been biased by the number of studies for each condition.

Chang et al (2022) conducted a meta-analysis of 7 double-blind RCTs (N=462) that used rTMS to treat methamphetamine use disorder.⁴⁰ All studies targeted the left DLPFC and the number of sessions ranged among studies from 5 to 20. Mean craving scores at baseline ranged from 22.63 to 57.68. A random effects model showed that clinical craving scores were significantly lower with rTMS than sham treatment (SMD, 0.983; 95% CI, 0.620 to 1.345; $p \leq .001$; $I^2=67.814\%$). According to a subgroup analysis, intermittent theta burst stimulation had a greater effect than 10-Hz rTMS. The authors concluded that further trials with larger sample sizes are needed.

NEUROLOGICAL DISORDERS OTHER THAN MIGRAINE

Amyotrophic Lateral Sclerosis or Motor Neuron Disease

Systematic Review

A Cochrane review by Fang et al (2013) identified 3 RCTs with a total of 50 participants with amyotrophic lateral sclerosis that compared rTMS with sham TMS.⁴¹ All trials were considered of poor methodologic quality. Heterogeneity prevented pooling of results, and the high rate of attrition further increased the risk of bias. Reviewers concluded that evidence was insufficient to draw conclusions about the efficacy and safety of rTMS in the treatment of amyotrophic lateral sclerosis.

Chronic Pain

Systematic Reviews

A Cochrane review by O'Connell et al (2018) evaluating noninvasive brain stimulation techniques was first published in 2010 and was updated in 2014⁴² and 2018.⁴³ The reviewers identified 42 RCTs (range 4 to 70 participants) on TMS for chronic pain. Meta-analysis of rTMS studies vs sham for pain intensity at short-term follow-up (0 to < 1 week postintervention) demonstrated a small effect with heterogeneity (SMD -0.22, 95%CI -0.29 to -0.16, low-quality evidence). This equates to a 7% (95% CI 5% to 9%) reduction in pain, or a 0.40 (95% CI 0.53 to 0.32) point reduction on a 0 to 10 pain intensity scale, which did not meet the minimum clinically important difference threshold of 15% or greater. There is very low-quality evidence that single doses of high-frequency rTMS of the motor cortex may have short-term effects on chronic pain and QOL but multiple sources of bias exist that may have influenced the observed effects. We did not find evidence that low frequency rTMS, rTMS applied to the dorsolateral prefrontal cortex and cranial electrotherapy stimulation are effective for reducing pain intensity in chronic pain.

Jiang et al (2022) conducted a systematic review and meta-analysis of 38 RCTs that assessed the analgesic effect of rTMS in 1338 patients with neuropathic pain.⁴⁴ A single rTMS session was used in 13 studies and multiple sessions were used in the remaining 25 studies. The overall risk of bias in most studies was low or uncertain. According to a random effects analysis, rTMS was superior to sham therapy in reducing pain scores (effect size, -0.66; 95% CI, -0.87 to -0.46; $p < .001$; $I^2=78\%$). Beneficial effects of rTMS on pain were observed at 1 month ($p < .001$) and 2 months ($p = .01$). Low-frequency rTMS (≤ 1 Hz) did not effectively reduce pain compared to higher frequency stimulation. The analysis did not find an increased risk of adverse events with rTMS compared to sham therapy. The authors concluded that larger, well-designed trials are needed to determine the long-term effect of rTMS in this setting.

Epilepsy

Systematic Reviews

A Cochrane review by Chen et al (2016) included 7 RCTs on low-frequency rTMS for epilepsy, 5 of which were completed studies with published data.⁴⁵ The total number of participants was 230. All studies had active or placebo controls and four were double-blinded. However, a meta-analysis could not be conducted due to heterogeneity in designs, interventions, and outcomes of the trials. Therefore, a qualitative synthesis was performed. For the outcome of seizure rate, two studies showed a significant reduction and five studies did not. Of the four studies evaluating the mean number of epileptic discharges, three studies showed a statistically significant reduction in discharges. Adverse events were uncommon and mild, involving headaches, dizziness, and tinnitus. There were no significant changes in medication use.

A more recent meta-analysis conducted by Mishra and colleagues (2020) included 7 RCTs that compared rTMS with sham or placebo controls in patients with epilepsy.⁴⁶ Two of the included studies showed statistically significant reductions in the seizure rate from baseline, 3 trials failed to show any statistically significant difference in seizure frequency, and 2 had unclear results due to inadequate power. In a meta-regression, when adjusted for other potential variables such as the type of coil used, stimulation frequency, and the total duration of the active intervention, seizure frequency worsened by 2.00 ± 0.98 ($p=0.042$) for each week of lengthening of the posttreatment follow-up period. These results suggested that rTMS exerted only a short-term effect. The reviewers concluded that although the procedure may be a therapeutic alternative for patients with drug-resistant epilepsy, further RCTs using standardized protocols and with adequate sample sizes and duration are still needed.

Fibromyalgia

Systematic Reviews

Su et al (2021) conducted a meta-analysis of 18 RCTs (N=643) with rTMS in patients with fibromyalgia.⁴⁷ Reduction in disease influence according to the Fibromyalgia Impact Questionnaire showed a significant effect of rTMS (SMD, -0.7 ; 95% CI, -1.173 to -0.228). The effect of rTMS on disease influence, pain, depression, and anxiety lasted for at least 2 weeks after the last session. Older patients were most likely to experience reduced Fibromyalgia Impact Questionnaire scores. The authors concluded that larger RCTs are needed to confirm these findings.

Saltychev and Laimi (2017) published a meta-analysis of rTMS for the treatment of patients with fibromyalgia.⁴⁸ The meta-analysis included 7 sham-controlled double-blinded trials with a low risk of bias. Trial sample sizes ranged from 18 to 54 patients. Five studies provided high-frequency stimulation to the left primary motor cortex, and the others were to the right or left DLPFC. The number of sessions ranged from 10 to 24, and follow-up ranged from immediately after treatment to 3 months posttreatment. In the pooled analysis, pain severity decreased after the last simulation by 1.2 points (95% CI, -1.7 to -0.8 points) on a 10-point numeric rating scale, while pain severity measured at 1 week to 1 month after the last simulation decreased by 0.7 points (95% CI, -1.0 to -0.3 points). Both were statistically significant but not considered clinically significant, based on a minimal clinically important difference of 1.5 points.

Parkinson Disease

A meta-analysis by Chou et al (2015) included 20 sham-controlled randomized trials (total n=470 patients) evaluating Parkinson disease.⁴⁹ Sample sizes ranged from 8 to 102 patients. The total effect size of low and high frequency rTMS on Unified Parkinson's Disease Rating Scale part III score was 0.46, which is considered a small-to-medium effect size, and the mean change in the Unified Parkinson's Disease Rating Scale part III score (-6.42) was considered a clinically important difference. The greatest effect on motor symptoms was from high frequency rTMS over the primary motor cortex (SMD=0.77, p<.001) and low frequency rTMS over other frontal regions (SMD=0.50, p=.008). High frequency rTMS at other frontal regions and low-frequency rTMS over the primary motor cortex did not have a statistically significant benefit. The largest trial included in the systematic review was an exploratory, multicenter, double-blind trial reported by Shirota et al (2013) who randomized 106 patients to 8 weeks of 1-Hz rTMS, 10-Hz rTMS, or sham stimulation over the supplementary motor area.⁵⁰ At 9 weeks, all groups showed a similar amount of improvement.

Li et al (2022) conducted a meta-analysis of 32 sham-controlled RCTs of rTMS in patients with Parkinson disease and motor dysfunction (N=1048 patients).⁵¹ Motor dysfunction was assessed using the United Parkinson's Disease Rating Scale part III score. Overall, rTMS had a significant effect on motor symptoms compared to sham (SMD, 0.64; 95% CI, 0.47 to 0.80; p<.0001; I²=64%). High-frequency rTMS to the primary motor cortex was the most effective intervention. Significant benefit of rTMS was also demonstrated for akinesia, rigidity, and tremor.

Stroke Recovery

Systematic Reviews

A number of RCTs and systematic reviews have evaluated rTMS for recovery from stroke. For example, a Cochrane review by Hao et al (2013) included 19 RCTs (N=588) evaluating the effect of low and high frequency TMS for improving function after stroke.⁵² The 2 largest trials (n=183 patients) showed that rTMS was not associated with a significant improvement in Barthel Index scores. Four trials (n=73) found no significant effect on motor function. Subgroup analyses for different stimulation frequencies or durations of illness also did not show a significant benefit of rTMS compared with sham rTMS or no treatment. Reviewers concluded that current evidence did not support the routine use of rTMS for the treatment of stroke.

A meta-analysis by Le et al (2014) assessed the effect of rTMS on the recovery of hand function and excitability of the motor cortex after stroke.⁵³ Eight RCTs (N=273) were selected. The quality of the trials was rated moderate to high, although the size of the studies was small. There was variability in the time since stroke (5 days to 10 years), in the frequency of rTMS applied (1-25 Hz for 1 second to 25 min/d), and the stimulation sites (primary motor cortex or premotor cortex of the unaffected hemisphere). Meta-analysis found a positive effect on finger motor ability (4 studies; n=79 patients; SMD=0.58) and hand function (3 studies; n=74 patients; SMD=-0.82), but no significant change in motor evoked potentials (n=43) or motor threshold (n=62).

A meta-analysis by Li et al (2015) included 4 RCTs on low-frequency rTMS over the right parstriangularis for patients (N=137) with aphasia after stroke.⁵⁴ All studies used double-blinding, but therapists were not blinded. Every trial used a different outcome measure, and sample sizes were small (range, 12-40 patients). Meta-analysis showed a medium effect size for naming ($p=.004$), a trend for a benefit on repetition ($p=.08$), and no significant benefit for comprehension ($p=.18$). Additional study in a larger number of patients would be needed to determine with greater certainty the effect of this treatment on aphasia after stroke.

Qiao et al (2022) performed a meta-analysis of RCTs that assessed the effect of rTMS in 433 patients with post-stroke dysphagia.⁵⁵ Twelve trials that used dysphagia severity rating scales (Dysphagia Grade and Penetration Aspiration Scale) were included. The specific controls used in each study were not specified. Study characteristics included duration of treatment of 1 to 10 days, stimulation frequency of 1 to 10 Hz, and duration of stimulation of 5 to 20 minutes. The analysis favored rTMS (SMD, -0.67; 95% CI, -0.88 to -0.45; $p<.001$; $I^2=42\%$). Subgroup analyses identified treatment duration >5 days and rTMS during the subacute phase after stroke as potential situations with greater clinical benefit, but there was no difference in efficacy according to stimulation frequency, location, or duration of each stimulation. The authors noted that publication bias was present and there may be limited clinical applicability of the dysphagia rating scales.

Zhang et al (2017) published a systematic review and meta-analysis evaluating the effects of rTMS on upper-limb motor function after stroke.⁵⁶ A search through October 2016 yielded 34 RCTs with a total of 904 participants (range, 6-108 participants). Pooled estimates found improvement with rTMS for both short-term (SMD=0.43; $p<.001$) and long-term (SMD=0.49; $p<.001$) manual dexterity. Of the 28 studies reporting on adverse events, 25 studies noted none. Mild adverse events, such as headache and increased anxiety were reported in three studies. The review was limited by variation in TMS protocols across studies.

Graef et al (2016) reported a systematic review of rTMS combined with upper-limb training for improving function after stroke.⁵⁷ Included were 11 sham-controlled randomized trials with 199 patients that evaluated upper-limb motor and functional status and spasticity; 8 RCTs with sufficient data were included in the meta-analysis. These studies were considered to have a low-to-moderate risk of bias. In the overall analysis, there was no benefit of rTMS on upper-limb function or spasticity (SMD=0.03; 95% CI, -0.25 to 0.32).

Section Summary: Psychiatric or Neurologic Disorders Other Than Depression, Migraine, or Obsessive-Compulsive Disorder

For individuals who have psychiatric disorders other than depression or OCD (eg, panic disorder, generalized anxiety disorder, posttraumatic stress disorder, schizophrenia, substance use disorder and craving) who receive rTMS, the evidence includes numerous small RCTs and meta-analyses of these studies. The trials included in the meta-analyses are typically small and of low methodologic quality. In addition, stimulation parameters have not been established, and trial results are heterogeneous. A number of sham-controlled randomized trials and meta-analyses of these have found a medium effect size of rTMS for the reduction of substance dependence or food craving. Most studies examined acute craving after 1 or 2 rTMS sessions, and there is limited evidence on the longer-term efficacy of this treatment approach. There are no large, high-quality trials for any of these conditions demonstrating efficacy or the durability of any treatment effects.

For individuals who have neurological disorders other than migraine (eg, amyotrophic lateral sclerosis, chronic pain, epilepsy, fibromyalgia, Parkinson disease, and stroke) who receive rTMS, the evidence includes numerous small RCTs and meta-analyses of these randomized trials. The trials included in the meta-analyses are typically small and of low methodologic quality. In addition, stimulation parameters have not been established, and trial results are heterogeneous. There are no large, high-quality trials for any of these conditions demonstrating efficacy or the durability of any treatment effects.

Summary of Evidence

For individuals who have treatment-resistant depression (TRD) who receive transcranial magnetic stimulation (TMS), the evidence includes a large number of sham-controlled randomized trials (RCTs) and meta-analyses of these trials. Relevant outcomes are symptoms, functional outcomes, and quality of life. Meta-analyses found improved response rates and rates of remission for conventional TMS and theta burst stimulation compared with sham TMS. Additionally, a head-to-head trial showed noninferiority of theta burst stimulation to conventional TMS, with no difference in the incidence of adverse events. Meta-analyses have concluded that the effect of TMS, on average depression scores, is smaller than the effect of electroconvulsive therapy (ECT) on TRD and that the mean improvement in depression scores with TMS did not reach the minimal clinically important difference; however, clinically meaningful improvements were noted in a subgroup of studies using higher frequency pulses. One potential area of benefit for TMS is in accelerating or enhancing the response to antidepressant medications, and there is some evidence that TMS, when given in conjunction with the initiation of pharmacologic therapy, improves the response rate compared with pharmacologic therapy alone. The effect of TMS appears to be less robust when it is given in combination with a stable dose of antidepressant medication. Meta-analyses have also found that the efficacy of TMS decreases with longer follow-up, though some studies have reported persistent response up to six months in some patients. There is limited evidence to compare the effects of these treatments on cognition, although the adverse events of TMS appear to be minimal. While meta-analyses have reported that the effect of TMS is smaller than the effect of electroconvulsive therapy on treatment-resistant depression, because TMS does not require general anesthesia or induce seizures, some individuals may decline ECT so the balance of incremental benefits and harms associated with TMS may be reasonable compared with ECT. Based on the short-term benefit observed in RCTs and the lack of alternative treatments, aside from ECT in patients with TRD, TMS may be considered a treatment option in patients with TRD who meet specific criteria. The evidence for theta burst stimulation includes a large randomized trial showing noninferiority with another method of TMS; no significant differences were noted in the number of adverse events. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have migraine headaches who receive TMS, the evidence includes a sham-controlled RCT of 201 patients conducted for submission to the Food and Drug Administration (FDA) for clearance in 2013. Relevant outcomes are symptoms, functional outcomes, and quality of life. The systematic review found that repetitive TMS (rTMS) reduced migraine pain intensity and frequency compared to sham; it was unclear whether patients were receiving background pharmacotherapy. The trial results were limited by the 46% dropout rate and the use of a post hoc analysis. No recent studies have been identified with these devices. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have obsessive-compulsive disorder (OCD) who receive TMS, the evidence includes a number of small-to-moderate sized sham-controlled double-blind RCTs and meta-analyses of these studies. Relevant outcomes are symptoms, functional outcomes, and quality of life. A meta-analysis of 15 RCTs (N=483, range 18-65) conducted in 2016, found a benefit of TMS on patient-reported OCD symptom severity at time points ranging from 2 to 6 weeks, but there was substantial variability in the stimulation parameters, including the cortical region that was stimulated and the frequency of stimulation. A meta-analysis conducted in 2021 included 26 RCTs. The primary analysis found a significant effect of rTMS compared to sham on OCD symptoms, but the effect seemed to last only until 4 weeks after the last treatment. The RCT that was the basis of FDA clearance of deep TMS for treatment of OCD compared deep TMS to sham in 99 patients for 6 weeks, with an additional 4 weeks of follow-up as a secondary outcome. Using a modified intention-to-treat (ITT) analysis (n=94), there was a larger mean decrease from baseline (improvement) on the Yale-Brown Obsessive Compulsive Scale (YBOCS) score (the primary efficacy outcome) in the active treatment group (-6.0 points) than the sham group (-2.8 points), translating to a moderate effect size of 0.69. At 6 weeks, the response rate was 38.1% in the active treatment group compared to 11.1% in the sham group (p=.003), as measured by a 30% or greater increase in the YBOCS. The difference in the primary outcome measure between active and sham groups was not statistically significant in the ITT analysis. There was a benefit for TMS on clinician-reported measures of improvement. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have psychiatric or neurological disorders other than depression, migraine, or OCD (eg, bipolar disorder, generalized anxiety disorder, panic disorder, posttraumatic stress disorder, schizophrenia, substance use disorder and craving, amyotrophic lateral sclerosis, chronic pain, epilepsy, fibromyalgia, Parkinson disease, stroke recovery) who receive TMS, the evidence includes numerous small RCTs and meta-analyses of these randomized trials. Relevant outcomes are symptoms, functional outcomes, and quality of life. The trials included in the meta-analyses are typically small and of low methodologic quality. In addition, stimulation parameters have not been established, and trial results are heterogeneous. There are no large, high-quality trials for any of these conditions demonstrating efficacy or the durability of any treatment effects. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Clinical Input Received From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, Blue Cross Blue Shield Association received input from 1 physician specialty society and 3 academic medical centers while their policy was under review in 2014. The reviewers considered rTMS to be medically necessary for TRD. Input agreed with the proposed criteria for treatment of TRD with rTMS, as included in the policy statement.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Child and Adolescent Psychiatry

The American Academy of Child and Adolescent Psychiatry (2013) published practice parameters on the assessment and treatment of children and adolescents with tic disorders.⁵⁸ The Academy did not recommend rTMS, citing the limited evidence on the safety, ethics, and long-term impact on development.

American Psychiatric Association

The American Psychiatric Association (2018) published consensus recommendations on repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression.⁵⁹ The guidelines state, "Multiple randomized controlled trials and published literature have supported the safety and efficacy of rTMS antidepressant therapy." The recommendations include information on the following variables: clinical environment, operator requirements, documentation, coils, cortical targets, coil positioning methods, determination of motor threshold, number of treatment sessions for acute treatment, and allowable psychotropic medications during TMS treatment.

The American Psychiatric Association's (2007, reaffirmed in 2012) guidelines on the treatment of patients with obsessive-compulsive disorder have indicated that "findings of the four published trials of repetitive TMS (rTMS) are inconsistent, perhaps because the studies differed in design, stimulation sites, duration, and stimulation parameters. The available results and the technique's non-invasiveness and good tolerability should encourage future research, but the need for daily treatment may limit the use of TMS in practice."

Veteran's Affairs/Department of Defense

The 2022 Veteran's Affairs/Department of Defense guideline for management of major depressive disorder recommends offering rTMS to patients who have experienced partial response or no response to an adequate trial of 2 or more pharmacologic treatments (strength of recommendation: weak).⁶² Recommended options for the second treatment attempt after the initial therapy tried include switching to another antidepressant or adding augmentation therapy with a second-generation antipsychotic. The recommendation for rTMS was graded as weak due to limitations of the available literature including small study effects, high rates of discontinuation, lack of allocation concealment, and the practical limitations of the need for daily treatment and lack of widespread access to facilities that offer this therapy. The guideline also concluded that there is limited evidence to recommend for or against theta-burst stimulation for treatment of depression.

The 2023 VA/DoD guideline for management of bipolar disorder states "for individuals with bipolar disorder who have demonstrated partial or no response to pharmacologic treatment for depressive symptoms, we suggest offering repetitive transcranial magnetic stimulation [rTMS] as an adjunctive treatment."⁶³ However, the recommendation was rated as "weak" and the confidence in the evidence was very low. For the management of PTSD, the 2023 guideline found insufficient evidence for or against rTMS.⁶⁴

National Institute for Health and Care Excellence

In 2015, the National Institute for Health and Care Excellence (NICE) provided revised guidance, stating that evidence on the short-term efficacy of rTMS for depression is adequate, although the clinical response is variable and some patients may not benefit.⁶¹

In 2014, the NICE provided guidance on the use of rTMS for treating and preventing migraine.⁶² The guidance stated that evidence on the efficacy of TMS for the treatment of a migraine was limited in quantity and for the prevention of a migraine was limited in both quality and quantity. Evidence on its safety in the short- and medium-term is adequate, but there was uncertainty about the safety of long-term or frequent use of TMS.

In 2020, the NICE stated that rTMS has not demonstrated any major safety concerns for management of obsessive-compulsive disorder or auditory hallucinations, but evidence for both uses is lacking; therefore, NICE recommends that rTMS be used in patients with these conditions only in the context of research.^{63,64}

International Neuromodulation Society/North American Neuromodulation Society

In 2020, an expert consensus panel from the International Neuromodulation Society-North American Neuromodulation Society performed a literature review and published recommendations for transcranial magnetic stimulation in the treatment of pain and headache.⁶⁵ For neuropathic pain, the panel recommended transcranial magnetic stimulation to the primary motor cortex (high level evidence) or the left dorsolateral prefrontal cortex (F3 location) (at least moderate level evidence). For postoperative pain, the panel recommended that transcranial magnetic stimulation to the F3 location be only selectively offered due to at least moderate certainty that the net benefit is small. For primary headache, the panel only based 2 recommendations on moderate certainty evidence: single transcranial magnetic stimulation for acute migraine and high-frequency rTMS to the primary motor cortex for migraine prevention. For posttraumatic brain injury, high level evidence supported a recommendation for high-frequency transcranial magnetic stimulation to the primary motor cortex or the F3 location.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 16.

Table 16. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Unpublished			
NCT02910024	Theta-Burst-Stimulation in Early Rehabilitation of Stroke (TheSiReS)	150	Sep 2022
NCT03556722	Effectiveness and Tolerability of Repetitive Transcranial Magnetic Stimulation For Preventive Treatment Of Episodic Migraine: A Single Centre, Randomised, Double-Blind, Sham-Controlled Phase 2 Trial	76	Apr 2022
Ongoing			
NCT06545474	Repetitive Transcranial Magnetic Stimulation (rTMS) as an Early Intervention in Major Depression (MD) Compared to Antidepressant Selective Serotonin Reuptake Inhibitor (SSRI) Medication (Early-TMS)	106	Dec 2026
NCT06370988	Theta-Burst Stimulation for Bipolar Depression	124	May 2029
NCT06524505	Efficacy, Tolerability, and Cognitive Effects of Deep Transcranial Magnetic Stimulation for Bipolar Depression: a Double-blind, Randomized Controlled Trial	100	Oct 2024
NCT02927236	Neuroplasticity Following Theta-Burst Stimulation in Cocaine Use Disorder	170	Dec 2022
NCT05389670	Theta-burst Repetitive Transcranial Magnetic Stimulation (TBS) of the Right Inferior Frontal Gyrus for Treatment of Nicotine Dependence	60	Apr 2023
NCT05331937	Transcranial Magnetic Stimulation (TMS) for Patients With Exposure Therapy-resistant Obsessive-compulsive Disorder (OCD): TETRO - a Multicenter Randomized Controlled Trial	250	Sep 2027
NCT05100888	Theta-burst rTMS in Schizophrenia to Ameliorate Negative and Cognitive Symptoms: a Double-blind, Randomized Clinical Trial	90	Dec 2025

NCT: national clinical trial

Government Regulations

National:

There is no national coverage determination for this topic.

Local:

Wisconsin Physicians Service Insurance Corporation, Local Coverage Determination (LCD): Transcranial Magnetic Stimulation (TMS) (L34641)

Original effective date: 10/01/2015

Revision effective date: 04/25/2024

Coverage Indications, Limitations, and/or Medical Necessity

Transcranial magnetic stimulation (TMS) is a noninvasive method of brain stimulation. The technique involves placement of a small coil over the scalp and passing a rapidly alternating current through the coil wire which produces a magnetic field that passes unimpeded through the brain. Depending on stimulation parameters (frequency, intensity, pulse duration,

stimulation site), repetitive TMS (rTMS) to specific cortical regions can either increase or decrease the excitability of the affected brain structures. The procedure is usually carried out in an outpatient setting and does not require anesthesia or analgesia.

When used as an antidepressant therapy, TMS produces a clinical benefit without the systemic side effects attendant with standard oral medications. TMS does not have adverse effects on cognition. Unlike electroconvulsive therapy (ECT), rTMS does not induce amnesia or seizures.

Indications for Coverage

TMS may be covered if prescribed and administered by a licensed physician who is knowledgeable in the use of repetitive transcranial magnetic stimulation. Outpatient rTMS may be indicated for patients with DSM-IV defined Major Depressive Disorder who have failed to benefit from initial treatment of their depression.

Initial Treatment

Left Prefrontal rTMS of the brain is considered medically necessary for use in an adult who has a confirmed diagnosis of severe major depressive disorder (MDD) single or recurrent episode; and

One or more of the following:

- Resistance to treatment with psychopharmacologic agents as evidenced by a lack of a clinically significant response to one trial of psychopharmacologic agents in the current depressive episode from at least two different agent classes. Each agent in the treatment trial must have been administered at an adequate course of mono- or poly-drug therapy; or
- Inability to tolerate psychopharmacologic agents as evidenced by two trials of psychopharmacologic agents from at least two different agent classes, with distinct side effects; or
- History of response to rTMS in a previous depressive episode; or
- If patient is currently receiving electro-convulsive therapy, rTMS may be considered reasonable and necessary as a less invasive treatment option.

AND

A trial of an evidence-based psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration without significant improvement in depressive symptoms as documented by standardized rating scales that reliably measure depressive symptoms.

AND

The order for treatment (or retreatment) is written by a psychiatrist (MD or DO) who has examined the patient, and reviewed the record. The physician will have experience in administering TMS therapy. The treatment shall be given under direct supervision of this physician (physician present in the area, but does not necessarily personally provide the treatment).

Coverage Limitations

The benefits of TMS use must be carefully considered against the risk of potential side effects in patients with any of the following:

- Seizure disorder or any history of seizures (except those induced by ECT or isolated febrile seizures in infancy without subsequent treatment or recurrence); or
- Presence of acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform or schizoaffective disorder) in the current depressive episode; or
- Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, history of repetitive or severe head trauma, or primary or secondary tumors in the central nervous system, or
- Presence of an implanted magnetic-sensitive medical device located less than or equal to 30 cm from the TMS magnetic coil or other implanted metal items including, but not limited to a cochlear implant, implanted cardiac defibrillator (ICD), pacemaker, Vagus nerve stimulator (VNS), or metal aneurysm clips or coils, staples or stents. (Dental amalgam fillings are not affected by the magnetic field and are acceptable for use with TMS).

All other uses of Transcranial Magnetic are experimental and are not covered.

Retreatment

Retreatment may be considered for patients who met the guidelines for initial treatment and subsequently developed relapse of depressive symptoms if the patient responded to prior treatments as evidenced by a greater than 50% improvement in standard rating scale measurements for depressive symptoms.

Wisconsin Physicians Service Insurance Corporation, Local Coverage Article: Billing and Coding: Transcranial Magnetic Stimulation (TMS) (A57598)

Original effective date: 11/01/2019

Revision effective date: 04/25/2024

Utilization Guidelines

The treatment must be provided by use of a device approved by the FDA for the purpose of supplying TMS.

It is expected that the services would be performed as indicated by current medical literature and standards of practice. Services performed in excess of established parameters may be subject to review for medical necessity.

TMS is reasonable and necessary for up to 20 visits over a 4-week period followed by five visits for tapering for those in remission; for those who show at least a 25% improvement by means of the standard tests for depression, the therapy may be continued for an additional 2 weeks (an addition 10 visits) with an additional 6 visits for tapering.

Retreatment may be considered for patients who met the guidelines for initial treatment and subsequently developed relapse of depressive symptoms if the patient responded **to prior** treatments as evidenced by a greater than 50% improvement in standard rating scale measurements for depressive symptoms or if there were a relapse after remission (e.g., GDS, PHQ-9, BDI, HAM-D, MADRS, QIDS or IDS-SR score.) A repeat treatment program is allowed as above.

Maintenance therapy is considered experimental/investigational and therefore not medically necessary.

(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)

Related Policies

- Vagus Nerve Stimulation
 - Electroconvulsive Therapy
-

References

1. FDA Briefing Document Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management (DSaRM) Advisory Committee Meeting February 12, 2019. <https://www.fda.gov/media/121376/download>. Accessed January 4, 2023
2. Zimmerman M, Chelminski I, Posternak M. A review of studies of the Montgomery-Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression. *Int Clin Psychopharmacol*. Jan 2004; 19(1): 1-7. PMID 15101563
3. Center for Drug Evaluation and Research Application Number: 211243Orig1s000 Summary Review https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000SumR.pdf. Accessed January 4, 2023.
4. Alphas L, Fu D-J, Williamson D, et al. Validation and mapping of the Suicidal Ideation and Behavior Assessment Tool (SIBAT). (abstract W88) *Neuropsychopharmacology*. 2018;43:S427S428.
5. Gross M, Nakamura L, Pascual-Leone A, et al. Has repetitive transcranial magnetic stimulation (rTMS) treatment for depression improved? A systematic review and meta-analysis comparing the recent vs. the earlier rTMS studies. *Acta Psychiatr Scand*. Sep 2007; 116(3): 165-73. PMID 17655557
6. Schutter DJ. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis. *Psychol Med*. Jan 2009; 39(1): 65-75. PMID 18447962
7. Sehatzadeh Sh, Tu HA, Palimaka S, et al. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Ont Health Technol Assess Ser*. 2016; 16(5): 1-66. PMID 27099642
8. Brunoni AR, Chaimani A, Moffa AH, et al. Repetitive Transcranial Magnetic Stimulation for the Acute Treatment of Major Depressive Episodes: A Systematic Review With Network Meta-analysis. *JAMA Psychiatry*. Feb 01 2017; 74(2): 143-152. PMID 28030740
9. Voigt JD, Leuchter AF, Carpenter LL. Theta burst stimulation for the acute treatment of major depressive disorder: A systematic review and meta-analysis. *Transl Psychiatry*. May 28 2021; 11(1): 330. PMID 34050123
10. Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression

- (THREE-D): a randomised non-inferiority trial. *Lancet*. Apr 28 2018; 391(10131): 1683-1692. PMID 29726344
11. Food and Drug Administration. 510(k) Summary: Brainsway deep TMS System (K122288). 2013; https://www.accessdata.fda.gov/cdrh_docs/pdf12/k122288.pdf Accessed 1/9/24.
 12. Kedzior KK, Reitz SK, Azorina V, et al. Durability of the antidepressant effect of the high-frequency repetitive transcranial magnetic stimulation (rTMS) In the absence of maintenance treatment in major depression: a systematic review and meta-analysis of 16 double-blind, randomized, sham-controlled trials. *Depress Anxiety*. Mar 2015; 32(3): 193-203. PMID 25683231
 13. Dunner DL, Aaronson ST, Sackeim HA, et al. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. *J Clin Psychiatry*. Dec 2014; 75(12): 1394-401. PMID 25271871
 14. Richieri R, Guedj E, Michel P, et al. Maintenance transcranial magnetic stimulation reduces depression relapse: a propensity-adjusted analysis. *J Affect Disord*. Oct 2013; 151(1): 129-35. PMID 23790811
 15. Connolly KR, Helmer A, Cristancho MA, et al. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. *J Clin Psychiatry*. Apr 2012; 73(4): e567-73. PMID 22579164
 16. Janicak PG, Nahas Z, Lisanby SH, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. *Brain Stimul*. Oct 2010; 3(4): 187-99. PMID 20965447
 17. Saltychev M, Juhola J. Effectiveness of high-frequency repetitive transcranial magnetic stimulation (rTMS) in migraine - a systematic review and meta-analysis. *Am J Phys Med Rehabil*. Jan 14 2022. PMID 35034064
 18. Food and Drug Administration. De Novo classification request for cerena transcranial magnetic stimulator (TMS) device. 2013; https://www.accessdata.fda.gov/cdrh_docs/reviews/K130556.pdf. Accessed January 9, 2023.
 19. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. *Arch Gen Psychiatry*. Nov 1989; 46(11): 1006-11. PMID 2684084
 20. Storch EA, De Nadai AS, Conceicao do Rosario M, et al. Defining clinical severity in adults with obsessive-compulsive disorder. *Compr Psychiatry*. Nov 2015; 63: 30-5. PMID 26555489
 21. Farris SG, McLean CP, Van Meter PE, et al. Treatment response, symptom remission, and wellness in obsessive-compulsive disorder. *J Clin Psychiatry*. Jul 2013; 74(7): 685-90. PMID 23945445
 22. Trevizol AP, Shiozawa P, Cook IA, et al. Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: An Updated Systematic Review and Meta-analysis. *J ECT*. Dec 2016; 32(4): 262-266. PMID 27327557
 23. Liang K, Li H, Bu X, et al. Efficacy and tolerability of repetitive transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. *Transl Psychiatry*. May 28 2021; 11(1): 332. PMID 34050130

24. Carmi L, Tendler A, Bystritsky A, et al. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. *Am J Psychiatry*. Nov 01 2019; 176(11): 931-938. PMID 31109199
25. Perera MPN, Mallawaarachchi S, Miljevic A, et al. Repetitive Transcranial Magnetic Stimulation for Obsessive- Compulsive Disorder: A Meta-analysis of Randomized, Sham-Controlled Trials. *Biol Psychiatry Cogn Neurosci Neuroimaging*. Oct 2021; 6(10): 947-960. PMID 33775927
26. U.S. Food and Drug Administration. De novo classification request for Brainsway Deep Transcranial Magnetic Stimulation System. 2018; https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170078.pdf Accessed 1/9/23.
27. Konstantinou G, Hui J, Ortiz A, et al. Repetitive transcranial magnetic stimulation (rTMS) in bipolar disorder: A systematic review. *Bipolar Disord*. Feb 2022; 24(1): 10-26. PMID 33949063
28. Tee MMK, Au CH. A Systematic Review and Meta-Analysis of Randomized Sham-Controlled Trials of Repetitive Transcranial Magnetic Stimulation for Bipolar Disorder. *Psychiatr Q*. Dec 2020; 91(4): 1225-1247. PMID 32860557
29. Cui H, Jiang L, Wei Y, et al. Efficacy and safety of repetitive transcranial magnetic stimulation for generalised anxiety disorder: A meta-analysis. *Gen Psychiatr*. 2019; 32(5): e100051. PMID 31673675
30. Li H, Wang J, Li C, et al. Repetitive transcranial magnetic stimulation (rTMS) for panic disorder in adults. *Cochrane Database Syst Rev*. Sep 17 2014; (9): CD009083. PMID 25230088
31. Mantovani A, Aly M, Dagan Y, et al. Randomized sham controlled trial of repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex for the treatment of panic disorder with comorbid major depression. *J Affect Disord*. Jan 10 2013; 144(1-2): 153-9. PMID 22858212
32. Trevizol AP, Barros MD, Silva PO, et al. Transcranial magnetic stimulation for posttraumatic stress disorder: an updated systematic review and meta-analysis. *Trends Psychiatry Psychother*. Jan-Mar 2016; 38(1): 50-5. PMID 27074341
33. He H, Lu J, Yang L, et al. Repetitive transcranial magnetic stimulation for treating the symptoms of schizophrenia: A PRISMA compliant meta-analysis. *Clin Neurophysiol*. May 2017; 128(5): 716-724. PMID 28315614
34. Dougall N, Maayan N, Soares-Weiser K, et al. Transcranial magnetic stimulation (TMS) for schizophrenia. *Cochrane Database Syst Rev*. Aug 20 2015; (8): CD006081. PMID 26289586
35. Guan HY, Zhao JM, Wang KQ, et al. High-frequency neuronavigated rTMS effect on clinical symptoms and cognitive dysfunction: a pilot double-blind, randomized controlled study in Veterans with schizophrenia. *Transl Psychiatry*. Feb 25 2020; 10(1): 79. PMID 32098946
36. Kumar N, Vishnubhatla S, Wadhawan AN, et al. A randomized, double blind, sham-controlled trial of repetitive transcranial magnetic stimulation (rTMS) in the treatment of negative symptoms in schizophrenia. *Brain Stimul*. May 2020; 13(3): 840-849. PMID 32289715
37. Zhuo K, Tang Y, Song Z, et al. Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial. *Neuropsychiatr Dis Treat*. 2019; 15: 1141-1150. PMID 31190822

38. Zhu L, Zhang W, Zhu Y, et al. Cerebellar theta burst stimulation for the treatment of negative symptoms of schizophrenia: A multicenter, double-blind, randomized controlled trial. *Psychiatry Res.* Nov 2021; 305: 114204. PMID 34587567
39. Jansen JM, Daams JG, Koeter MW, et al. Effects of non-invasive neurostimulation on craving: a meta-analysis. *Neurosci Biobehav Rev.* Dec 2013; 37(10 Pt 2): 2472-80. PMID 23916527
40. Chang CH, Liou MF, Liu CY, et al. Efficacy of Repetitive Transcranial Magnetic Stimulation in Patients With Methamphetamine Use Disorder: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. *Front Psychiatry.* 2022; 13: 904252. PMID 35711590
41. Fang J, Zhou M, Yang M, et al. Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease. *Cochrane Database Syst Rev.* May 31 2013; (5): CD008554. PMID 23728676
42. O'Connell NE, Wand BM, Marston L, et al. Non-invasive brain stimulation techniques for chronic pain. *Cochrane Database Syst Rev.* Apr 11 2014; (4): CD008208. PMID 24729198
43. O'Connell NE, Marston L, Spencer S, et al. Non-invasive brain stimulation techniques for chronic pain. *Cochrane Database Syst Rev.* Apr 13 2018; 4: CD008208. PMID 29652088
44. Jiang X, Yan W, Wan R, et al. Effects of repetitive transcranial magnetic stimulation on neuropathic pain: A systematic review and meta-analysis. *Neurosci Biobehav Rev.* Jan 2022; 132: 130-141. PMID 34826512
45. Chen R, Spencer DC, Weston J, et al. Transcranial magnetic stimulation for the treatment of epilepsy. *Cochrane Database Syst Rev.* Aug 11 2016; (8): CD011025. PMID 27513825
46. Mishra A, Maiti R, Mishra BR, et al. Effect of Repetitive Transcranial Magnetic Stimulation on Seizure Frequency and Epileptiform Discharges in Drug-Resistant Epilepsy: A Meta-Analysis. *J Clin Neurol.* Jan 2020; 16(1): 9-18. PMID 31942753
47. Su YC, Guo YH, Hsieh PC, et al. Efficacy of Repetitive Transcranial Magnetic Stimulation in Fibromyalgia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Clin Med.* Oct 12 2021; 10(20). PMID34682790
48. Saltychev M, Laimi K. Effectiveness of repetitive transcranial magnetic stimulation in patients with fibromyalgia: a meta-analysis. *Int J Rehabil Res.* Mar 2017; 40(1): 11-18. PMID 27977465
49. Chou YH, Hickey PT, Sundman M, et al. Effects of repetitive transcranial magnetic stimulation on motor symptoms in Parkinson disease: a systematic review and meta-analysis. *JAMA Neurol.* Apr 2015; 72(4): 432-40. PMID 25686212
50. Shirota Y, Ohtsu H, Hamada M, et al. Supplementary motor area stimulation for Parkinson disease: a randomized controlled study. *Neurology.* Apr 09 2013; 80(15): 1400-5. PMID 23516319
51. Li R, He Y, Qin W, et al. Effects of Repetitive Transcranial Magnetic Stimulation on Motor Symptoms in Parkinson's Disease: A Meta-Analysis. *Neurorehabil Neural Repair.* Jul 2022; 36(7): 395-404. PMID 35616427
52. Hao Z, Wang D, Zeng Y, et al. Repetitive transcranial magnetic stimulation for improving function after stroke. *Cochrane Database Syst Rev.* May 31 2013; (5): CD008862. PMID 23728683
53. Le Q, Qu Y, Tao Y, et al. Effects of repetitive transcranial magnetic stimulation on hand function recovery and excitability of the motor cortex after stroke: a meta-analysis. *Am J Phys Med Rehabil.* May 2014; 93(5): 422-30. PMID 24429509

54. Li Y, Qu Y, Yuan M, et al. Low-frequency repetitive transcranial magnetic stimulation for patients with aphasia after stroke: A meta-analysis. *J Rehabil Med*. Sep 2015; 47(8): 675-81. PMID 26181486
55. Qiao J, Ye QP, Wu ZM, et al. The Effect and Optimal Parameters of Repetitive Transcranial Magnetic Stimulation on Poststroke Dysphagia: A Meta-Analysis of Randomized Controlled Trials. *Front Neurosci*. 2022; 16: 845737. PMID 35573312
56. Zhang L, Xing G, Fan Y, et al. Short- and Long-term Effects of Repetitive Transcranial Magnetic Stimulation on Upper Limb Motor Function after Stroke: a Systematic Review and Meta-Analysis. *Clin Rehabil*. Sep 2017; 31(9): 1137-1153. PMID 28786336
57. Graef P, Dadalt MLR, Rodrigues DAMDS, et al. Transcranial magnetic stimulation combined with upper-limb training for improving function after stroke: A systematic review and meta-analysis. *J Neurol Sci*. Oct 15 2016; 369: 149-158. PMID 27653882
58. Murphy TK, Lewin AB, Storch EA, et al. Practice parameter for the assessment and treatment of children and adolescents with tic disorders. *J Am Acad Child Adolesc Psychiatry*. Dec 2013; 52(12): 1341-59. PMID 24290467
59. McClintock SM, Reti IM, Carpenter LL, et al. Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. *J Clin Psychiatry*. Jan/Feb 2018; 79(1). PMID 28541649
60. Papakostas GI, Trivedi MH, Shelton RC, et al. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. *Mol Psychiatry*. Aug 2024; 29(8): 2287-2295. PMID 38454079
61. Brown R, Cherian K, Jones K, et al. Repetitive transcranial magnetic stimulation for post-traumatic stress disorder in adults. *Cochrane Database Syst Rev*. Aug 02 2024; 8(8): CD015040. PMID 39092744
62. VA/DoD Clinical Practice Guideline. (2022). The Management of Major Depressive Disorder. Washington, DC: U.S. Government Printing Office.
<https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf>.
63. VA/DoD Clinical Practice Guideline. (2023). VA/DoD Clinical Practice Guideline for Management of Bipolar Disorder. Washington, DC: U.S. Government Printing Office.
<https://www.healthquality.va.gov/guidelines/MH/bd/VA-DoD-CPG-BD-Full-CPGFinal508.pdf>.
64. VA/DoD Clinical Practice Guideline. (2023). VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder. Washington, DC: U.S. Government Printing Office.
<https://www.healthquality.va.gov/guidelines/MH/ptsd/VA-DoD-CPG-PTSD-Full-CPGAug242023.pdf>.
65. National Institute for Health and Care Excellence (NICE). Repetitive transcranial magnetic stimulation for depression [IPG542]. 2015; <https://www.nice.org.uk/guidance/ipg542>
66. National Institute for Health and Care Excellence (NICE). Transcranial magnetic stimulation for treating and preventing migraine [IPG477]. 2014;
<https://www.nice.org.uk/guidance/ipg477>
67. National Institute for Health and Care Excellence (NICE). Transcranial magnetic stimulation for obsessive- compulsive disorder [IPG676]. 2020;
<https://www.nice.org.uk/guidance/ipg676>
68. National Institute for Health and Care Excellence (NICE). Transcranial magnetic stimulation for auditory hallucinations [IPG680]. 2020;
<https://www.nice.org.uk/guidance/ipg680/chapter/1-Recommendations> Accessed 1/9/24.

69. Leung A, Shirvalkar P, Chen R, et al. Transcranial Magnetic Stimulation for Pain, Headache, and Comorbid Depression: INS-NANS Expert Consensus Panel Review and Recommendation. *Neuromodulation*. Apr 2020; 23(3): 267-290. PMID 32212288
70. Wisconsin Physicians Service Insurance Corporation, Local Coverage Determination (LCD): Transcranial Magnetic Stimulation (TMS) (L34641). Original effective date: 10/01/2015, Revision effective date: 4/25/2024.
71. Wisconsin Physicians Service Insurance Corporation, Local Coverage Article: Billing and Coding: Transcranial Magnetic Stimulation (TMS) (A57598). Original effective date: 11/01/2019, Revision effective date: 04/25/2024.

The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through January, 2025 the date the research was completed.

Joint BCBSM/BCN Medical Policy History

Policy Effective Date	BCBSM Signature Date	BCN Signature Date	Comments
8/9/02	7/31/02	8/9/02	Joint policy established
2/28/05	2/28/05	4/6/05	Routine maintenance
7/1/07	5/10/07	5/28/07	Code Update
3/1/09	12/21/08	12/9/08	Routine maintenance
7/1/10	4/20/10	4/20/10	Routine maintenance
9/1/11	6/21/11	6/21/11	Routine maintenance; code updates, 0160T and 0161T deleted; new CPT codes 90867 and 90868 added.
5/1/12	2/21/12	2/21/12	Routine maintenance; code updates; new CPT code 90869 added and nomenclature for CPT codes 90867 and 90868 updated.
9/1/13	6/18/13	6/26/13	Status changed to established with criteria.
9/1/15	6/19/15	7/16/15	Routine maintenance
7/1/16	4/19/16	5/23/16	Routine maintenance References and rationale updated Criteria updated to address requests for repeat rTMS therapy and additional inclusionary criteria post JUMP Added updated local coverage determination for Medicare
7/1/17	4/18/17	4/18/17	Routine maintenance
11/1/17	8/15/17	8/15/17	Routine maintenance References and rationale updated
11/1/18	8/21/18	8/21/18	Routine maintenance
11/1/19	8/20/19		Routine maintenance
11/1/20	8/18/20		Routine maintenance Inclusion criteria edited
11/1/21	10/20/21		Routine maintenance Added under exclusion for *OCD with mention OCD may be reviewed

			for individual consideration based on review of applicable medical records.
11/1/22	8/16/22		<p>Routine maintenance</p> <p>Added ref 21.</p> <p>Clarification re: who can administer TMS.</p> <p>Added to exc: chronic pain, spasticity</p>
5/1/23	3/29/23		<p>Maintain TMS for OCD on an individual basis, added for refractory OCD defined as two therapeutic trials of medications and psychotherapy with one augmentation episode that has failed” under the Inclusions section under OBSESSIVE-COMPULSIVE DISORDER (OCD).</p> <p>Updated exclusion section under bullet 1 – removed chronic pain and spasticity. Added migraine headaches as an exclusion to this bullet.</p> <p>Updated inclusion section under bullet 4 based on BCBSA update: The individual has tried and had an inadequate response to 2 antidepressant agents from 2 different antidepressant classes (i.e., selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, bupropion, or mirtazapine). An adequate trial of an antidepressant is defined by BOTH of the following:</p> <ol style="list-style-type: none"> 1. The trial length was at least 6 weeks at generally accepted doses or of sufficient duration as determined by the treating physician at the generally accepted doses; AND 2. Individual was ≥80% adherent to the agent during the trial. <p>On the BCN (HMO) side BCN’s Behavioral Health Dept reviews</p>

			<p>requests, on the BCBS (PPO) side Behavioral Health (BH) is managed by New Directions but per Dr. Beecroft the BH vendor is not a full carve out and manages our covered services.</p> <p>Post JUMP: Per Dr. Onwuzurike's recommendation: under the Inclusion criteria under Major Depressive Disorders (MDD), # 6 "Conditions that must be met during the entire TMS treatment" moved to after the obsessive compulsive disorder (OCD) section as this applies to both MDD and OCD.</p> <p>Per Dr. Konieczny's edit – updated section summary pg 24 and summary of evidence pg 36 to reflect that the evidence is sufficient to determine that the technology results in an improvement in the net health outcome for OCD. (ky)</p>
5/1/24	2/20/24		<p>Routine maintenance.</p> <p>Added code 0858T under EST when billed with a JUMP approved diagnosis which is depression or OCD.</p> <p>Vendor: BC Behavioral Health. (ky)</p>
9/1/24	6/11/24		<p>Policy coming early to add new FDA indication for TMS. NeuroStar Advanced Therapy is indicated as an adjunct for the treatment of Major Depressive Disorder (MDD) in adolescent patients (age 15-21) was FDA approved on 3/22/24.</p> <p>Updated "tail out or tapering sessions to the number of treatments to both MDD and OCD section under the Inclusions section.</p> <p>Vendor: BC Behavioral Health. (ky)</p>
5/1/25	2/18/25		<p>Routine maintenance</p> <p>Vendor: BC Behavioral Health. (ky)</p>

Next Review Date: 1st Qtr, 2026

BLUE CARE NETWORK BENEFIT COVERAGE

POLICY: TRANSCRANIAL MAGNETIC STIMULATION AS A TREATMENT OF DEPRESSION AND OTHER PSYCHIATRIC/NEUROLOGIC DISORDERS

I. Coverage Determination:

Commercial HMO (includes Self-Funded groups unless otherwise specified)	Covered, policy criteria apply.
BCNA (Medicare Advantage)	See Government Regulations section.
BCN65 (Medicare Complementary)	Coinsurance covered if primary Medicare covers the service.

II. Administrative Guidelines:

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee of coverage.